Language selection

Search

Patent 2511807 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent Application: (11) CA 2511807
(54) English Title: HEMOSTATIC COMPOSITIONS AND USES THEREFOR
(54) French Title: COMPOSITIONS HEMOSTATIQUES ET UTILISATIONS LEUR CONVENANT
Status: Dead
Bibliographic Data
(51) International Patent Classification (IPC):
  • A61B 17/04 (2006.01)
  • A61B 17/00 (2006.01)
  • A61L 24/00 (2006.01)
  • A61L 26/00 (2006.01)
  • A61B 17/12 (2006.01)
(72) Inventors :
  • VOURNAKIS, JOHN N. (United States of America)
  • FINKIELSZTEIN, SERGIO (United States of America)
(73) Owners :
  • MARINE POLYMER TECHNOLOGIES, INC. (United States of America)
(71) Applicants :
  • MARINE POLYMER TECHNOLOGIES, INC. (United States of America)
(74) Agent: OSLER, HOSKIN & HARCOURT LLP
(74) Associate agent:
(45) Issued:
(86) PCT Filing Date: 2003-12-31
(87) Open to Public Inspection: 2004-07-22
Examination requested: 2008-12-22
Availability of licence: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): Yes
(86) PCT Filing Number: PCT/US2003/041762
(87) International Publication Number: WO2004/060172
(85) National Entry: 2005-06-27

(30) Application Priority Data:
Application No. Country/Territory Date
60/437,349 United States of America 2002-12-31

Abstracts

English Abstract




The present invention relates generally to the field of hemostasis, including
methods, compositions, and devices that can be employed to achieve hemostasis
at an increased rate. More specifically the present invention relates to
hemostatic compositions that achieve a hemostatic effect at a distance from
the site of application of the composition, and a method for administering
such a composition to effectively reduce localized vascular complications
associated with treating a breach or puncture in a vein or artery and reduce
the time to achieve hemostasis.


French Abstract

La présente invention concerne d'une façon générale le domaine de l'hémostase, et notamment de procédés, compositions et dispositifs qu'il est possible d'employer pour réaliser l'hémostase à une vitesse accrue. L'invention concerne plus particulièrement, d'une part des compositions qui produisent un effet hémostatique à distance du site d'application de la composition, et d'autre part un procédé permettant l'administration d'une telle composition de façon, non seulement à réussir à réduire les complications vasculaires localisées associées au traitement d'une coupure ou d'une perforation d'une veine ou d'une artère, mais aussi à réduire le temps nécessaire pour produire l'hémostase.

Claims

Note: Claims are shown in the official language in which they were submitted.





What is claimed is:


1. A method for treating a puncture in a vein or artery resulting from a
cardiac
catheterization procedure in a patient, comprising:
a) applying topically to the patient's skin over a catheter exit site a
composition
comprising an effective amount of a vasoconstrictor, wherein the
vasoconstrictor does not
comprise a poly-.beta.-1.fwdarw. 4 N-acetylglucosamine polymer or derivative
thereof, and wherein the
catheter exit site is contiguous with the catheter puncture in the vein or
artery by 1-10 cm;
and concurrently
b) applying compression to the punctured vein or artery,
wherein a cessation or reduction of blood flow out of the breach or puncture
in the
vein or artery is achieved in 30%-50% less time than applying compression in
conjunction
with a topical barrier-forming material without said vasoconstrictor.

2. A method for treating a puncture in a femoral artery resulting from a
cardiac
catheterization procedure in a patient, comprising:
a) applying topically to the patient's skin over a catheter exit site a
composition
comprising an effective amount of a vasoconstrictor, wherein the
vasoconstrictor does not
comprise a poly-.beta.-1.fwdarw. 4 N-acetylglucosamine polymer or derivative
thereof, and wherein the
catheter exit site is contiguous with the catheter puncture in the femoral
artery by 1-10 cm;
and concurrently
b) applying compression to the punctured vein or artery,
wherein a cessation or reduction of blood flow out of the breach or puncture
in the
femoral artery is achieved in 30%-50% less time than applying compression in
conjunction
with a topical barrier-forming material without said vasoconstrictor.

3. A method for inhibiting the formation of hematomas resulting from a cardiac
catheterization procedure in a patient, comprising:


-57-




a) applying topically to the patient's skin over a catheter exit site
contiguous by
1-10 cm with a catheter puncture in a vein or artery a composition comprising
an effective
amount of a vasoconstrictor, wherein the vasoconstrictor does not comprise a
poly-.beta.-1.fwdarw. 4 N-
acetylglucosamine polymer or derivative thereof;
b) concurrently applying compression to the punctured vein or artery; and
c) recording the number of hematomas formed,
wherein the formation of hematomas is inhibited in comparison to applying
compression in conjunction with a topical barrier-forming material without
said
vasoconstrictor.

4. The method of any one of claims 1, 2, or 3 wherein the vasoconstrictor is
endothelin, endothelin-1, epinephrine, adrenaline, metaraminol bitartrate,
dopamine HCl,
isoproterenol HCl, norepinephrine, phenylephrine, serotonin, thromboxane,
norepinephrine,
prostaglandin, methergine, oxytocin, isopreland U-46619, papaverine,
yohimbine, visnadin,
khellin, bebellin, or nicotinate derivatives.

5. The method of any one of claims 1, 2, or 3, wherein the composition further
comprises an anti-fungal or antibacterial agent.

6. The method of any one of claims 1, 2, or 3, wherein the composition further
comprises collagen.

7. The method of any one of claims 1, 2, or 3, wherein the composition further
comprises a pharmaceutical carrier.

8. The method of any one of claims 1, 2, or 3, wherein the composition is
formulated as a gel, solid, liquid, sponge, foam, spray, emulsion, suspension,
or solution.


-58-



9. The method of any one of claims 1, 2, or 3, wherein the composition further
comprises a neutral liquid, neutral gel or neutral solid.

10. The method of claim 9, wherein the composition further comprises a neutral
solid and wherein the neutral solid is a gauze.

11. The method of claim 8, wherein the composition is in the form of a coating
on
a neutral solid.

12. The method of claim 11, wherein the neutral solid is a gauze.

13. The method of any one of claims 1, 2, or 3, wherein the barrier-forming
material is a gauze.

14. The method of any one of claims 1, 2, or 3, wherein the composition
further
comprises a coagulant selected from the group consisting of alpha-2-
antiplasmin, alpha-1-
antitrypsin, alpha-2-macroglobulin, aminohexanoic acid, aprotinin, a source of
Calcium ions,
calcium alginate, calcium-sodium alginate, casein Kinase II, chitin, chitosan,
collagen,
cyanoacrylates, epsilon-aminocaproic acid, Factor XIII, fibrin, fibrin glue,
fibrinogen,
fibronectin, gelatin, living platelets, metha crylates, PAI-1, PAI-2, plasmin
activator inhibitor,
plasminogen, platelet agonists, protamine sulfate, prothrombin, an RGD
peptide, sphingosine,
a sphingosine derivative, thrombin, thromboplastin, and tranexamic acid.

15. The method of any one of claims 1, 2, or 3, wherein the patient is a
human.

16. The method of any one of claims 1, 2, or 3, wherein composition applied is
a
film or membrane.



-59-


17. The method of claim 16, wherein the film or membrane comprises a barrier-
forming material.

18. The method of any one of claims 1, 2, or 3, wherein composition is
formulated
as a mat, string, microbead, microsphere, or microfibril.

19. The method of any one of claims 1, 2, or 3, wherein the composition
further
comprises a biodegradable material.

20. The method of claim 19, wherein the biodegradable material is selected
from
the group consisting of a polyanionic polysaccharide, alginic acid, collagen,
a polypeptide, a
polyglycolide, a polylactide, a polycaprolactone, dextran and a copolymer of
dextran, a
polyglycolide, a polylactide, a polydioxanone, a polyestercarbonate, a
polyhydroxyalkonate,
and a polycaprolactone and a copolymer thereof.

21. The method of any one of claims 1, 2, or 3, further comprising before step
(a)
the step of administering to the patient an anticoagulant.

22. The method of claim 21, wherein the anticoagulant is selected from the
group
consisting of coumadin, heparin, nadroparin, asparin, and a thrombolytic
agent.

23. The method of claim 22, wherein the composition further comprises
protamine
sulfate in an amount effective to neutralize heparin.

24. The method of any one of claims 1, 2, or 3, wherein the artery is the
femoral,
radial, brachial, or axillary artery.


-60-




25. The method of any one of claims 1, 2, or 3, wherein the vein is the
femoral,
internal jugular, or subclavian vein.

26. The method of any one of claims 1, 2, or 3, wherein the compression is
manual compression.

27. The method of any one of claims 1, 2, or 3, wherein the compression is
mechanical compression.

28. The method of any one of claims 1, 2, or 3, wherein the compression is
applied to the vein or artery proximal of the puncture or breach.

29. The method of any one of claims 1, 2, or 3, wherein the compression is
applied at the site of application of the composition.

30. The method of any one of claims 1, 2, or 3, wherein the compression is
applied with a compression bandage.

31. The method of any one of claims 1, 2, or 3, further comprising, repeating
step
(b).

32. The method of claim 31, wherein the rate is at least 10% greater than
applying
compression in conjunction with a topical barrier-forming material without a
vasoconstrictor.

33. The method of claim 31, wherein the rate is at least 20% greater than
applying
compression in conjunction with a topical barrier-forming material without a
vasoconstrictor.



-61-



34. The method of claim 31, wherein the rate is at least 30% greater than
applying
compression in conjunction with a topical barrier-forming material without a
vasoconstrictor.

35. The method of claim 31, wherein the rate is at least 40% greater than
applying
compression in conjunction with a topical barrier-forming material without a
vasoconstrictor.

36. The method of claim 31, wherein the rate is at least 50% greater than
applying
compression in conjunction with a topical barrier-forming material without a
vasoconstrictor.

37. The method of any one of claims 1, 2, or 3, wherein the vein or artery is
breached or punctured by a catheter.

38. The method of any one of claims 1, 2, or 3, wherein the skin wound
contiguous with the breach or puncture in the vein or artery is 10, 9, 8, 7,
6, 5, or 4 cm from
the puncture in the vein or artery.

39. A method for decreasing the occurrence of localized vascular complications
comprising:
a) applying topically to the patient's skin over a wound contiguous with a
breach
or puncture in a vein or artery a composition comprising a vasoconstrictor,
wherein the
vasoconstrictor does not comprise a poly-.beta.-1.fwdarw.4 N-acetylglucosamine
polymer or derivative
thereof;
b) concurrently applying compression to the breached or punctured vein or
artery; and
c) recording the occurrence of localized vascular complications,



-62-



wherein an amount of the vasoconstrictor is effective to cause sealing of the
breach or
puncture in the vein or artery, reducing the rate of localized vascular
complications in
comparison to applying compression in conjunction with a topical barrier-
forming material
without a vasoconstrictor.

40. The method of claim 39, wherein the rate is 50% less than applying
compression in conjunction with a topical barrier without a vasoconstrictor.

41. The method of claim 39, wherein the vein or artery is breached or
punctured
by a catheter.


-63-

Description

Note: Descriptions are shown in the official language in which they were submitted.




CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
HEMOSTATIC COMPOSITIONS AND USES THEREFOR
This application claims priority of U.S. provisional patent application Serial
No. 60/437,349, filed December 31, 2002, which is incorporated herein by
reference in its
entirety.
1. FIELD OF THE INVENTION
The present invention relates generally to the field of hemostasis, including
methods, compositions, and devices that can be employed to achieve hemostasis
at an
increased rate or in a reduced period of time. More specifically the present
invention relates
to hemostatic compositions that achieve a hemostatic effect at a distance from
the site of
application of the composition, and a method for administering such a
composition to
effectively reduce localized vascular complications associated with treating a
breach or
puncture in a vein or artery. The hemostatic compositions can comprise one or
more
vasoconstrictors or one or more coagulants, or a combination of one or more
vasoconstrictors
with one or more coagulants. The hemostatic compositions can also comprise a
compound
that has both vasoconstrictive properties and coagulant properties. The
hemostatic
compositions can be applied in conjunction with a barrier-forming material to
more
effectively achieve hemostasis and reduce the occurrence of localized vascular
complications.
2. BACKGROUND
Localized vascular complications associated with catheterization of a vein or
artery are common side effects with many medical procedures. Such
complications including
hemorrhaging of blood vessels, delayed hemostasis time, hematoma,
pseudoaneurysm, and
arteriovenous (AV) fistula formation can be life threatening. Since cardiac
catheterization
remains the primary technique for diagnosing coronary artery disease and is
used to help
delineate coronary anatomy, the information gained is often a medical
necessity, despite the
risks. Traditionally, the application of pressure to a vein or artery effected
by a breach or
puncture was the preferred method for reducing complications, however
compression of a
_1_



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
vein or artery after cardiac catheterization can be very painful for the
patients. Compression
bandages with weights may be applied for 4-8 hours following hemostasis and
patients can be
immobilized up to 24 hours. Patients frequently develop back pain and urinary
retention in
addition to the localized vascular complications.
Two approaches have recently been used to reduce localized vascular
complications, namely percutaneous closurelsealant devices and hemostatic
patches.
Numerous hemostatic patches have been invented to treat superficial wounds
on skin or on the surface of internal organs. These patches are effective at
the site where the
patch contacts the skin or contacts the surface of an intenlal organ.
Application of the
patches in treatment of cardiac catheterization presents a problem in that the
underlying
puncture in the artery or vein is not directly effected by the active
components of the patches.
Thus, the vein or artery puncture may continue to bleed after the skin
puncture wound is
sealed and the possibility of hematoma formation or other localized vascular
complications
exists. U.S. patent no. 6,056,970 discloses a hemostatic biocompatable
composition and a
method of application wherein the composition is topically maintained in
contact with the
wound on the skin surface, preferably with light pressure, for a period of
time for clotting to
occur at the interface between the composition and the wound. A related
composition is
disclosed in U.S. patent no. 6,361,551, where a wound-contacting fabric
accelerates clot
formation at an interface between a wound surface and the hemostatic fabric.
The hemostatic
fabric is composed of collagen fibers and can comprise numerous hemostatic
agents. U.S.
patent no. 5,564,849 also discloses a similar patch that accelerates clot
formation at an
interface between a skin or organ wound surface and the hemostatic patch. The
patch
comprises active amounts of thrombin and epsilon aminocaproic acid (EACA).
Several compositions that can act as hemostatic agents and typically include
collagen or fibrin are known (Falstrom et al., 1997, Catheterization and
Cardiovasular
Diagnosis 41:79-84; Hoelcstra et al., 1998, Biomaterials. 19:1467-1471; Prior
et al., 2000,
Journal of Biomedical Materials Research. 53(3):252-257). The main
disadvantage of such
compositions is their limited use in treating breaches or punctures in veins
or arteries at a
distance. In order to treat breaches or punctures in veins or arteries at a
distance beneath the
skin surface with such compositions, it is necessary to apply the compositions
in an invasive
manner so that the compositions are in contact with a breach or puncture in a
vein or artery.
Since such compositions are effective at the site of contact, topical
treatment at a breach or
-2-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
puncture in a vein or artery that is found at some distance from the skin
surface is not
possible. U.S. patent No. 4,394,373 discloses compositions that act as
coagulants and may be
used to promote clotting of a wound by placing the compositions in contact
with the wound
where the composition comprises liquid or powder chitosan. U.S. Patent No.
5,510,102
discloses compositions that act as coagulants and may be used to promote
clotting of a wound
by placing the compositions in contact with the wound where the composition
comprises
platelet rich plasma plus a biocompatable polymer that is a hemostatic agent
such as alginate.
The compositions of U.S. Patent Nos. 4,394,373 and 5,510,102 are either
applied directly to
the wound surface, in the case of treatment of a superficial wound or in the
case of a puncture
in an artery left by a catheterization procedure, the compositions are
typically injected into
the soft tissue surrounding the arterial puncture site, so that the
composition is in contact with
the puncture site. The injection of the compositions is an invasive procedure
that can lead to
complications such as swelling, further damage to blood vessels and tissue,
and increased risk
of infection.
Hemostatic patches are effective at the interface of the wound and the patch.
Thus, in the case of a puncture in a vein or artery caused by catheterization,
when a patch
causes clotting at the skin surface wound site, the deeper internal puncture
in the vein or
artery continues to hemorrhage increasing the likelihood that a hematoma or
other vascular
complications will occur. Hemostatic patches have not been demonstrated to be
effective at a
distance in treating punctures resulting from catheterization, but nonetheless
hemostatic
patches have numerous surgical applications where the patches or fabrics can
be applied
directly to the wound surfaces on organs exposed during surgical procedures.
Another approach to reducing localized vascular complications associated
with catheterization procedures has been the development of devices to aid in
the application
of hemostatic compositions percutaneously, so that a hemostatic composition is
administered
in contact with the puncture site. Kipshidze et al. (U.S. 5,437,292) and Van
Tassel et al.
(U.S. 6,193,670 Bl) each invented a device for sealing catheter puncture sites
in blood
vessels. Such a device typically administers a plug composed of collagen or
fibrin that
extends from the site of the puncture in the vein or artery through the
catheter sheath tract to
the skin surface. Numerous variations of such device have been developed where
the
puncture site is sealed with a suture (Wood et al. U.S. 5,746,755), or where
the puncture in
the blood vessel is sealed from within the blood vessel lumen (Redmond et al.
U.S.
-3-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
200210006429 Al). Gwechenberger, Silber, Camenzind, and Sanborn each provided
a
comparison of sealant devices employed with compression compared with manual
compression alone (Camenzind et al, 1994, Journal of the American College of
Cardiology.
24(3):655-662;Gwechenberger et al., 1997, Angiology. 48(2):121-126; Sanborn et
al., 1993,
Journal of the American College of Cardiology. 22(5):1273-1279; Silber et al.,
1998,
Catheterization and Cardiovasular Diagnosis 43:421-427). Nearly, all
commercially
available devices and patches are suggested for use in conjunction with
compression. The
main disadvantage of such devices is the invasive manner in which the
compositions or
sutures are applied.
Although several hemostatic devices are commercially available, complication
rates with theses closure devices are similar to conventional manual
compression (Glade et
al., 2002, Emedicine Journal, 3(3):1-13). Devices and methods which do not
suture the
catheter arterial puncture, but plug the catheter tract with collagen from the
skin surface to the
arterial puncture site have also been shown to be no more effective than
manual compression
alone (Camenzind et al., 1994, Journal of the American College of Cardiology.
24(3):655-
662). Whether arterial puncture closure devices or hemostatic patches are used
to treat a
breach or puncture in a vein or artery, there remains a need for reducing the
incidence of life
threatening complications associated with catheterization and other procedures
which has
been a persistent medical problem which bespeaks the need for new treatments.
3. SiJMMARY OF THE INVENTION
The present invention provides methods and compositions for treatment for a
breach or puncture in a vein or artery that would decrease the occurrence of
hematomas and
other localized vascular complications. Without being bound by any theory, the
inventors
believe that the compositions and methods of the invention are effective in
tissues beyond the
site of contact with the skin surface wound relative to the devices and
patches of the art.
Thus, the compositions and methods of the invention provide the advantage and
decreased
likelihood of localized vascular complications. The main feature of the
methods and
compositions of the invention over the existing hemostatic patches and devices
is the non-
invasive manner in which the compositions function and can be applied.
-4-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
Accordingly, the present invention provides a method for treating a breach or
puncture in a vein or artery of a patient that comprises: a) applying
topically to the patient's
skin over a wound contiguous with the breach or puncture in the vein or artery
a composition
comprising an effective amount of a vasoconstrictor, wherein the
vasoconstrictor does not
comprise a poly-(3-1-~ 4 N-acetylglucosamine polymer or derivative thereof;
and concurrently
b) applying compression to the breached or punctured vein or artery, wherein a
cessation or
reduction of blood flow out of the breach or puncture in the vein or artery is
achieved at a
greater rate or in a reduced period of time than applying compression in
conjunction with a
topical barrier-forming material without a vasoconstrictor. In related
embodiments, the
composition further comprises a coagulant.
In other embodiments of the present invention, a method for achieving a
cessation of blood flow or sealing of a breach or puncture in a vein or artery
and a cessation
of blood flow or sealing of a skin surface wound that is contiguous with the
breach or
puncture comprises: a) applying topically to the patient's skin over a wound
contiguous with
a breach or puncture in a vein or artery a composition comprising a
vasoconstrictor or
coagulant, wherein the vasoconstrictor or coagulant does not comprise a poly-
,Q-1-j 4 N-
acetylglucosamine polymer or derivative thereof; b) concurrently applying
compression to
the breached or punctured vein or artery; and c) recording the amount of blood
flow from the
wound and the puncture, wherein an amount of the vasoconstrictor or coagulant
is effective
to increase sealing or increase cessation of blood flow from the breach or
puncture in the vein
or artery and increase sealing or increase cessation of blood flow from the
skin surface
wound, in comparison to applying compression in conjunction with a topical
barrier-forming
material without a vasoconstrictor.
In other embodiments of the present invention, a method for treating a breach
or puncture in a vein or artery of a patient, comprises: a) applying topically
to the patient's
skin over a wound contiguous with the breach or puncture in the vein or artery
a composition
comprising an effective amount of a coagulant, wherein the coagulant does not
comprise a
poly-~i-1-j 4 N-acetylglucosamine polymer or derivative thereof; and
concurrently b)
applying compression to the breached or punctured vein or artery, wherein a
cessation or
reduction of blood flow out of the breach or puncture in the vein or artery is
achieved at a
greater rate or in a reduced period of time than applying compression in
conjunction with a
topical barrier-forming material without a coagulant.
-5-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
In related embodiments, the compositions of the invention further comprise an
anti-fungal agent, an antibacterial agent, and/or collagen. In yet other
related embodiments,
the composition further comprises a pharmaceutical carrier. In certain
embodiments, the
composition is formulated as a gel, solid, liquid, sponge, foam, spray,
emulsion, suspension,
or solution. In yet other related embodiments, the composition further
comprises a neutral
liquid, neutral gel or neutral solid. In preferred embodiments, the
composition further
comprises a neutral solid and the neutral solid is a gauze. h1 other preferred
embodiments,
the composition is in the form of a coating on a neutral solid. In yet other
preferred
embodiments the barrier-forming material is a gauze.
The present invention provides for use of a coagulant with the compositions,
methods, and kits of the present invention described herein, wherein the
coagulant is selected
from the group consisting of alpha-2-antiplasmin, alpha-1-antitrypsin, alpha-2-

macroglobulin, aminohexanoic acid, aprotinin, a source of Calcium ions,
calcium alginate,
calcium-sodium alginate, casein kinase II, chitin, chitosan, collagen,
cyanoacrylates, epsilon-
aminocaproic acid, factor XIII, fibrin, fibrin glue, fibrinogen, fibronectin,
gelatin, living
platelets, metha crylates, plasminogen activator inhibitor-1 (PAI-1),
plasminogen activator
inhibitor-2 (PAI-2), plasmin activator inhibitor, plasminogen, platelet
agonists, protamine
sulfate, prothrombin, an RGD peptide, sphingosine, a sphingosine derivative,
thrombin,
thromboplastin, and tranexamic acid. In another embodiment of the invention,
any coagulant
that can be used in any of the methods of the present invention described
herein.
The present invention provides for use of a vasoconstrictor with the
compositions, methods, and kits of the present invention described herein,
wherein the
vasoconstrictor is selected from the group consisting of endothelin,
endothelin-1,
epinephrine, adrenaline, metaraminol bitartrate (for example, manufactured as
AramineTM),
dopamine HCl (for example, manufactured as IntropineTM), isoproterenol HCl
(for example,
manufactured as IsuprelTM), norepinephrine (for example, manufactured as
LevophedTM),
phenylephrine, SerotoninTM, thromboxane, norepinephrine, prostaglandin,
methergine,
oxytocin, isopreland U-46619, papaverine, yohimbine, visnadin, khellin,
bebellin, and
nicotinate derivatives. In an alternative embodiment, the present invention
provides for a
vasoconstrictor that can be used with the methods of the present invention
described herein,
with the proviso that the vasoconstrictor is not epinephrine.
-6-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
In certain embodiments of the methods of the invention, the patient is a
human.
In certain embodiments of the compositions, methods, and kits of the
invention, a film or membrane is used in conjunction with the vasoconstrictor
and/or
coagulant. In certain modes of theses embodiments, the film or membrane
comprises a
barrier-forming material. In yet other embodiments, the composition is
formulated as a mat,
string, microbead, microsphere, and/or microfibril.
The methods and compositions of the present invention provide for a
composition that comprises a vasoconstrictor and or coagulant and further
comprises a
biodegradable material. In certain embodiments, the biodegradable material is
selected from
the group consisting of polyanionic polysaccharides, alginic acid, collagen,
polyglycolide,
polylactide, polycaprolactone, dextran and copolymers thereof, polyglycolide,
polylactide,
polydioxanones, polyestercarbonates, polyhydroxyalkonates, polycaprolactone,
and
copolymers thereof. In certain embodiments, the compositions of the invention
are coated
with one or more of these biodegradable materials. hl other embodiments, the
compositions
of the invention are co formulated with one or more of these biodegradable
materials.
In preferred embodiments, the methods of the invention comprise the step of
administering to the patient an anticoagulant, and then applying topically to
the patient's skin
over a wound contiguous with the breach or puncture in the vein or artery a
composition
comprising an effective amount of a vasoconstrictor, wherein the
vasoconstrictor does not
comprise a poly-~i-1-~ 4 N-acetylglucosamine polymer or derivative thereof,
and concurrently
carrying out the step of applying compression to the breached or punctured
vein or artery. In
related preferred embodiments, the anticoagulant administered to a patient is
selected from
the group consisting of coumadin, heparin, nadroparin, aspirin, and a
thrombolytic agent. In
other related embodiments, the composition further comprises protamine sulfate
in an amount
effective to neutralize heparin. In other preferred embodiments, the patient
is administered
the anticoagulant comprising aspirin together with another agent selected from
the group
consisting of coumadin, heparin, nadroparin, and a thrombolytic agent. hl yet
other preferred
embodiments, the anticoagulant comprises one or more of coumadin, heparin,
nadroparin,
aspirin, or a thrombolytic agent.
The methods described herein can be used to treat a breach or puncture in any
vein or artery, including but not limited to the femoral, radial, brachial, or
axillary artery, and



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
the femoral, internal jugular, or subclavian vein. Descriptions and depictions
of the locations
of such blood vessels can be found in anatomy references including but not
limited to
Leonard, C. H. 1983, The concise Gray's Anatomy, Chartwell books, Secaucus,
NJ.
In certain preferred embodiments of the methods of the invention, the
compression that is applied is manual compression. In other embodiments of the
present
invention, the compression is mechanical compression. In related embodiments,
the
compression is applied to the vein or artery proximal of the pwicture or
breach. In other
related embodiments, the compression is applied at the site of application of
the composition.
In yet other embodiments, the compression is applied with a compression
bandage. In
preferred embodiments of the present invention, the methods of the invention
further
comprise, repeating the step of application of compression to the breached or
punctured vein
or artery.
In certain embodiments of the present invention, the rate of cessation or
reduction of blood flow out of the breach or puncture in the vein or artery
achieved by the
present methods involving the topical use of a vasoconstrictor is at least 10%
greater than
without the vasoconstrictor. hi other embodiments of the present invention,
the rate of
cessation or reduction of blood flow out of the breach or puncture in the vein
or artery is
20%, 30%, 40%, or 50% greater than applying compression in conjunction with a
topical
barrier-forming material without a vasoconstrictor. In preferred embodiments
of the present
invention, the vein or artery is breached or punctured by a catheter.
In certain embodiments of the present invention, the time to achieve cessation
or reduction of blood flow out of the breach or puncture in the vein or artery
is 10% less than
applying compression in conjunction with a topical barrier-forming material
without a
vasoconstrictor. In other embodiments of the present invention, the time to
achieve cessation
or reduction of blood flow out of the breach or puncture in the vein or artery
is 20%, 30%,
40%, or 50% less than applying compression in conjunction with a topical
barner-forming
material without a vasoconstrictor. In preferred embodiments of the present
invention, the
vein or artery is breached or punctured by a catheter.
The methods of the invention can be used to treat vascular breaches or
punctures in a patient by applying a composition of the invention to a portion
of the patient's
slcin that is contiguous with the breach or puncture. The portion of the skin
can be at any
distance from the breach or puncture, as long as the composition of the
invention is capable
_g_



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
of exerting an effect on the wound healing process. In certain embodiments,
the distance is
approximately 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 cm from the puncture in a vein
or artery. In a
preferred embodiment, the breach or puncture in a vein or artery is
approximately 8, 9, or 10
cm from a contiguous skin wound site. In another preferred embodiment, the
breach or
puncture in a vein or artery is approximately 4, 3, 2, or 1 cm from a
contiguous skin wound
site. In yet another preferred embodiment, the breach or puncture in a vein or
artery is
approximately 7, 6, or 5 cm from a contiguous skin wound site.
The present invention provides methods for decreasing the occurrence of
localized vascular complications in a patient. One such method comprises the
following
steps, a) applying topically to the patient's skin over a wound contiguous
with a breach or
puncture in a vein or artery a composition comprising a vasoconstrictor or
coagulant, wherein
the vasoconstrictor or coagulant does not comprise a poly-(3-1-~ 4 N-
acetylglucosamine
polymer or derivative thereof; b) concurrently applying compression to the
breached or
punctured vein or artery; and c) recording the occurrence of localized
vascular complications,
wherein an amount of the vasoconstrictor or coagulant is effective to cause
sealing of the
breach or puncture in the vein or artery, reducing the rate of localized
vascular complications
in comparison to applying compression in conjunction with a topical barrier-
forming material
without a vasoconstrictor. In certain preferred embodiments, the rate of
cessation or
reduction of blood flow out of the breach or puncture in the vein or artery is
at least 50%
greater than applying compression in conjunction with a topical barrier
without a
vasoconstrictor. In other preferred embodiments, the rate of cessation or
reduction of blood
flow out of the breach or puncture in the vein or artery is at least 10%, 20%,
30%, 40%, 50%,
60%, or 70% greater than applying compression in conjunction with a topical
barrier without
a vasoconstrictor. In certain preferred embodiments, the time to achieve
cessation or
reduction of blood flow out of the breach or puncture in the vein or artery is
at least 50% less
than applying compression in conjunction with a topical barrier without a
vasoconstrictor. In
other preferred embodiments, the time to achieve cessation or reduction of
blood flow out of
the breach or puncture in the vein or artery is at least 10%, 20%, 30%, 40%,
50%, 60%, or
70% less than applying compression in conjunction with a topical barner
without a
vasoconstrictor.
The present invention further provides a pharmaceutical composition for
topically treating a breach or puncture in a vein or artery wherein the
pharmaceutical
-9-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
composition comprises: a) an effective amount of a vasoconstrictor, wherein
the
vasoconstrictor does not comprise a poly-(3-1~ 4 N-acetylglucosamine polymer
or derivative
thereof; and b) a pharmaceutically acceptable carrier. In certain preferred
embodiments, the
pharmaceutical composition further comprises a coagulant. In other preferred
embodiments,
the pharmaceutical composition further comprises a neutral liquid, neutral gel
and/or neutral
solid. As used herein in relation to all embodiments of the invention, a
neutral liquid, neutral
gel and/or neutral solid means such agents have no activity or are inactive
with respect to
processes involved in hemostasis. The pharmaceutical composition can further
comprise a
gauze.
The present invention further provides a kit useful for practicing the present
methods that comprises in one or more containers a composition useful for
treating a breach
or puncture in a vein or artery, that comprises: a) an effective amount of a
vasoconstrictor,
wherein the vasoconstrictor does not comprise a poly-~i-1-j 4 N-
acetylglucosamine polymer
or derivative thereof; and b) a pharmaceutically acceptable carrier, and
instructions for
topically treating a breach or puncture in a vein or artery. The composition
can further
comprise a coagulant, a neutral liquid, a neutral gel and/or a neutral solid.
In a preferred
embodiment the composition further comprises a gauze. In another preferred
embodiment
the composition further comprises gelatin.
The present invention yet further provides a pharmaceutical composition for
topically treating a breach or puncture in a vein or artery wherein the
pharmaceutical
composition comprises: a) an effective amount of a vasoconstrictor, wherein
the
vasoconstrictor does not comprise a poly-(3-1-j 4 N-acetylglucosamine polymer
or derivative
thereof; and b) wherein the vasoconstrictor is formulated into a barrier,
membrane, or film.
The pharmaceutical composition can further comprise a coagulant. The
pharmaceutical
composition can further comprise a neutral liquid, neutral gel and/or neutral
solid. In a
preferred embodiment the composition further comprises gelatin.
The present invention yet further provides a kit useful for practicing the
present methods that comprises in one or more containers a composition that
comprises: a) an
effective amount of a vasoconstrictor, wherein the vasoconstrictor does not
comprise a
poly-(3-1-j 4 N-acetylglucosamine polymer or derivative thereof; and b)
wherein the
vasoconstrictor is formulated into a barner, membrane, or film, and
instructions for topically
treating a breach or puncture in a vein or artery. The composition can further
comprise a
-10-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
coagulant, a neutral liquid, a neutral gel and/or a neutral solid. In a
preferred embodiment the
composition further comprises gauze. In another preferred embodiment the
composition
further comprises gelatin.
In preferred embodiments, the compositions and methods of the invention
described herein can be used in treatment of catheter-induced punctures in
veins or arteries.
The treatment can comprise reducing hemostasis time, reducing the flow of
blood from the
catheter puncture in the blood vessel, and reducing the occurrence of
localized vascular
complications.
In particular, the methods of the present invention described herein are
useful
for the treatment of cardiac catheterization wounds. Such wounds commonly
result from
diagnostic or therapeutic cardiac intervention procedures such as coronary
angiography and
angioplasty. hi one embodiment, a method for treating a puncture in a vein or
artery resulting
from a cardiac catheterization procedure in a patient comprises: a) applying
topically to the
patient's skin over a catheter exit site a composition comprising an effective
amount of a
vasoconstrictor and/or coagulant, wherein the vasoconstrictor and/or coagulant
does not
comprise a poly-,Q-1~ 4 N-acetylglucosamine polymer or derivative thereof, and
wherein the
catheter exit site is contiguous with the catheter puncture in the vein or
artery by
approximately 1-10 cm; and concurrently b) applying compression to the
punctured vein or
artery, wherein a cessation or reduction of blood flow out of the breach or
puncture in the
vein or artery is achieved at a rate 30%-50% greater than applying compression
in
conjunction with a topical barner-forming material without a vasoconstrictor
and/or
coagulant.
In another embodiment, a method for treating a puncture in a vein or artery
resulting from a cardiac catheterization procedure in a patient comprises: a)
applying
topically to the patient's skin over a catheter exit site a composition
comprising an effective
amount of a vasoconstrictor and/or coagulant, wherein the vasoconstrictor
and/or coagulant
does not comprise a poly-~i-1-~ 4 N-acetylglucosamine polymer or derivative
thereof, and
wherein the catheter exit site is contiguous with the catheter puncture in the
vein or artery by
approximately 1-10 cm; and concurrently b) applying compression to the
punctured vein or
artery, wherein a cessation or reduction of blood flow out of the breach or
puncture in the
vein or artery is achieved in a measure of time that is 30%-50% less than
applying
-11-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
compression in conjunction with a topical barrier-forming material without a
vasoconstrictor
and/or coagulant.
The methods of the present invention are also useful for reducing the number
and size of hematomas such as those resulting from a cardiac catheterization
procedure in a
patient. The methods of the present invention are also useful for inhibiting
the formation of
hematomas such as those resulting from a cardiac catheterization procedure in
a patient. As
used herein in the context of the invention, "inhibiting the formation of
hematomas" means
decreasing the probability that a hematoma will form or decreasing the
probability that
hematomas of a large size, e.g., greater than 3 cm, will form. In one
embodiment, a method
of reducing the occurrence of a hematoma following cardiac catheterization
comprises: a)
applying topically to the patient's skin over a catheter exit site contiguous
by 1-10 cm with a
catheter puncture in a vein or artery a composition comprising an effective
amount of a
vasoconstrictor and/or coagulant, wherein the vasoconstrictor andlor coagulant
does not
comprise a poly-~3-1-j 4 N-acetylglucosamine polymer or derivative thereof; b)
concurrently
applying compression to the punctured vein or artery thereby reducing the
occurrence of
hematomas after cardiac catheterization. In certain embodiments, a reduction
in the
occurrence of hematomas is measured by recording the number of hematomas
formed in a
sample patient population, in comparison to a sample patient population
wherein compression
is applied to the patients in conjunction with a topical barner-forming
material without a
vasoconstrictor and/or coagulant.
3.1 Definitions
"Localized vascular complications" - Localized vascular complications
include hematomas, pseudoaneurysms, and AV fistula formations, and other
medical
conditions associated with a breach or puncture in a vein or artery.
"Hematoma"-- Hematomas are produced by of the invasion of other tissues by
blood tissue normally localized inside the blood vessels, resulting in
swelling of the invaded
tissues and tissues surrounding the invaded tissues.
"Barrier-forming material"--A barrier-forming material is any material that
can be placed on the surface of the skin over a wound and physically impede or
reduce blood
flow from the wound.
-12-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
"Concurrently" - concurrently as used herein, in relation to applying a
composition of the invention and compression to a patient, means either
applying
compression and a composition of the invention topically to a wound site on a
patient at the
same time, or applying a composition topically to a wound site on a patient
immediately (i. e.
any period of time less than 1 minute, or less than 2 minutes) followed by
application of
compression to the wound site on a patient. For example, if the composition of
the invention
is formulated as a barner forming material, then the composition and the
compression can be
applied at the same time. If the composition is for example a gel, the gel can
be applied to
the wound site followed immediately by compression, or the gel might be
applied to a
barrier-forming material such as gauze and the treated gauze can then be
applied at the same
time as compression. In all examples the application of the composition and
compression is
defined as concurrent.
4. BRIEF DESCRIPTION OF THE FIGURES
Figure 1. Ultrasonography of a human femoral artery. Top of image
correlates with slcin surface of patient, and cross hair symbol marks the
center of the blood
vessel at 2.67 cm below the skin surface.
5. DETAILED DESCRIPTION OF THE INVENTION
The present invention is based upon the concept of treating a breach or
puncture in a vein or artery from a distance via a skin surface wound
contiguous with the
breach or puncture. The present methods encompass topically applying to the
skin surface
wound a composition with vasoconstrictive and/or coagulating properties in
conjunction with
application of compression to the site or an proximal site of the vein or
artery to reduce blood
flow. The methods described herein seal or heal of the breach or puncture at a
greater rate or
in less time in comparison to available non-invasive treatments, i. e.
hemostatic patches,
compression. The invention also encompasses one or more compositions that can
be used in
the methods of the invention and kits that comprise one or more of the
compositions of the
invention for use in treating a breach or puncture in a vein or artery.
Thus, the present invention provides a solution for the problem of localized
vascular complications, such as hematomas, pseudoaneurysms, and AV fistula
formations,
-13-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
associated with treating a breach or puncture in a vein or artery. In
particular, the methods of
the invention described herein, are an improvement over both hemostatic
patches and arterial
closure devices in treating wounds resulting from medical procedures,
including but not
limited to cardiac catheterization procedures. Whereas the available
hemostatic patches act
directly at the site of contact with the wound, and only indirectly act on the
catheter puncture
in the artery or vein by decreasing blood flow, without being bound by any
theory, the
inventors believe that, the compositions and methods of the invention act on
the catheter
puncture in the artery or vein from a distance and stop or reduce blood flow
from the internal
puncture site at a greater rate or in less time than presently known devices,
decreasing the
likelihood of hematoma formation. For example a soluble vasoconstrictor may
act on
receptors present in a blood vessel, resulting in a constriction of the blood
vessel. The
methods of the present invention are an improvement over the invasive arterial
closure
devices used following cardiac catheterization. The advantages offered include
the ease of
carrying out the method steps, since no suture machines or application devices
need be
applied subcutaneously, and a decreased likelihood of hematoma formation. The
non-
invasive methods of the invention also minimize the risk of infections that
can occur when
foreign objects, such as the available arterial closure devices are inserted
through the layers
of a patients skin.
5.1 INJURIES FOR TREATMENT BY THE PRESENT METHODS AND
COMPOSITIONS
The present invention provides methods for treatment of a breach or puncture
in a vein or artery. The breach or puncture may be a wound of any origin or
cause. In an
embodiment of the invention, the breach or puncture in a vein or artery is
caused by an object
such as a bullet, knife, or surgical instrument. In a preferred embodiment the
obj ect that
causes a breach or puncture in the vein or artery is a catheter. In yet
another preferred
embodiment the puncture is the result of a cardiac catheterization procedure.
Arteries whose
breaches or punctures may be treated by the present methods and compositions
include, but
are not limited to, the femoral, radial, brachial, and axillary arteries.
Veins whose breaches or
punctures may be treated by the present methods and compositions include, but
are not
limited to, the femoral, internal jugular, and subclavian veins.
-14-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
Generally, when the breach or puncture in the vein or artery being treated by
the present methods and compositions results from cardiac catheterization, the
vein or artery
will have a breach or puncture can be caused by a smaller diameter catheter.
Examples of
smaller diameter catheters include catheters ranging from 4 F to 6 F in size (
F=French Units,
where 1F is equal to 0.33rnm). In another embodiment of the invention, the
breach or
puncture may be caused by a larger-diameter catheter ranging in size from 7 F
to 11.5 F
(Sanborn et al., 1993, Journal of the American College of Cardiology.
22(5):1273-1279).
Preferably, the artery is larger than a catheter between 6F and 8F in size. In
such
embodiments where a breach or puncture is the result of catheterization, the
methods and
compositions of the invention can be used to treat punctures or breaches cause
by various
types of catheters, including but not limited to a Swan-Ganz catheter, a Sones
catheter, and a
pigtail catheter (Glade et al., 2002, Emedicine Journal, 3(3):1-13).
In certain embodiments, catheters are inserted perpendicular to the skin
surface. W other embodiments, a catheter is inserted at an angle that is
20°- 40° to the skin
surface.
The present methods can be used to treat breaches or punctures in veins or
arteries in any mammal including but not limited to a human, dog, horse, cat,
rabbit, rat,
mouse, pig, cow, monlcey or sheep. Preferably the patient is a human.
5.2 METHODS FOR USING THE HEMOSTATIC COMPOSITIONS
The methods of the invention encompass topical administration of a
composition comprising a vasoconstrictor or a coagulant to a patient's skin
surface at a site of
a wound that is contiguous with a breach or puncture in a vein or artery.
Compositions of the
invention comprising vasoconstrictors and/or coagulants are further described
in section 5.5
below, and may include a barrier-forming component that is applied to the
slcin surface over a
wound that is contiguous with a breach or puncture in a vein or artery.
5.2.1 SITE OF APPLICATION OF HEMOSTATIC COMPOSITION
The present methods for treating vascular wounds can entail a combination of
applying pressure and/or a barrier-forming material and a composition of the
invention
comprising a vasoconstrictor or coagulant agent to a site on the patient's
skin surface wound
-15-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
that is contiguous with a breach or puncture in a vascular structure such as a
vein or artery.
In a preferred embodiment of the invention, a site of application on the skin
surface of the
composition of the invention, contiguous with a breach or puncture in the vein
or artery, is
within 10 cm of the site of a breach or puncture in a vein or artery. In
another embodiment,
the site of application is within approximately 9 cm, 8 cm, 7 cm, 6 cm, 5 cm,
4 cm, 3 cm, 2
cm, or 1 cm of a breach or puncture in the vein or artery. In yet another
embodiment, the site
of topical application is between 10 cm and 2 cm of a breach or puncture in
the vein or artery.
In a preferred embodiment the site of topical application is about 1-10 cm
from a breach or
puncture in the vein or artery.
5.2.2 APPLYING COMPRESSION
Compression can be indirectly applied to a breached or punctured vein or
artery in several ways. The present methods for treating vascular wounds can
entail a
combination of applying pressure and/or a barrier-forming material and a
composition of the
invention comprising a vasoconstrictor or coagulant agent to a site on the
patient's skin
surface wound that is contiguous with a breach or puncture in a vascular
structure such as a
vein or artery. When a vein or artery with a breach or puncture is subject to
compression,
blood flow and pressure decreases in the vein or artery, allowing the puncture
to seal or clot
with a decreased likelihood of hematoma formation.
In certain embodiments of the invention, the compression is manual
compression. Manual compression can be applied by pressing with the tips of
fingers on the
skin surface, at a point above an underlying vein or artery, so that the vein
or artery is
compressed and blood flow is significantly reduced or stopped in the targeted
vein or artery.
This type of compression can be applied at a site proximal of a breach or
puncture in a vein
or artery. Typically, an proximal site is between 1 and 10 cm proximal of the
breach or
puncture. The technique of manually pressing on a patients skin at the correct
place to reduce
blood flow and blood pressure is common in the art and is effective in both
humans and other
mammals (Camenzind et al, 1994, Journal of the American College of Cardiology.
24(3):655-662; Kipshidze et al., 1998, Journal of Invasive Cardiology.
10(3):133-141;
Merino et al., 1992, Catheterization and Cardiovasular Diagnosis 26:319-322;
Sanborn et al.,
1993, Journal of the American College of Cardiology. 22(5):1273-1279). The
manual
-16-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
compression can be optionally applied in combination with application of a
composition
comprising "a composition of the invention," comprising a vasoconstrictor or
coagulant.
Such embodiments entail manually compressing to subject a artery or vein to
compression
concurrently with applying a composition of the invention. Alternatively,
manual
compression can be applied immediately prior to application of a composition
of the
invention or immediately after application of a composition of the invention.
In an embodiment of the invention that encompasses a manual compression
technique as a part of a method of the invention, the technique may be one
wherein pressure
is applied with ones fingers or the palm of ones hand directly over a
dennotomy site that is
contiguous with a breach or puncture in the vein or artery (Sanborn et al.,
1993, Journal of
the American College of Cardiology. 22(5):1273-1279). In certain embodiments
where the
wound is caused by a catheter, compression can be applied directly to the
wound site at the
same angle that the catheter was inserted at. In one embodiment of the
invention, manual
compression may be applied concurrently with application of the composition.
If the
composition of the invention is formulated as a barner-forming material, then
the
composition and the compression can be applied at the same time. If the
composition is for
example a gel, the gel can be applied to the wound site followed immediately
by
compression, or the gel might be applied to a barrier-forming material such as
gauze and the
treated gauze can then be applied at the same time as compression.
In applying manual compression techniques, the amount of pressure applied
and the consistency of pressure force generally varies over time and among
individuals
applying the pressure. For this reason, it may be preferable to apply
compression to a
breached or punctured vein or artery mechanically rather than manually, to
ensure the
consistency of the force of the pressure applied. Several devices have been
developed and
are commonly used to apply compression, including C-clamps of varying or
adjustable force
and compression bandages/dressings with attachment of desired weights. Such
compression
devices may be used in conjunction with the methods and compositions of the
invention and
can provide a constant application of the desired compression force.
In certain embodiments, compression is either applied first at a site proximal
to the wound site to decrease blood flow in the vein or artery with the breach
or puncture or
compression is first applied to both the proximal site and the wound site
simultaneously, in
either case the compression applied at the proximal site is later released or
decreased while
-17-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
the compression at the wound site is maintained. The time between the
application of
compression and the release of pressure at the proximal site can be about 15
seconds, 30
seconds, 1 minute, 1.5 minutes, 2 minutes, 2.5 minutes, 3 minutes, 3.5
minutes, 4 minutes,
4.5 minutes, or 5 minutes. In other embodiments, compression is applied and
maintained at
both the proximal and wound sites.
In another embodiment, where the composition encompasses an adhesive
barrier-forming material, the composition can be topically adhered to cover a
skin surface
wound that is contiguous with a breach or puncture in a vein or artery without
applying
pressure to compress the vein or artery.
5.2.3 COMPRESSION TIME
One of the advantages of the methods of the present invention is that the
combination of compression and the compositions of the invention results in a
reduction in
compression time needed to stop or slow the flow of blood from the breach or
puncture
relative to compression alone. The amount of time for which compression is
maintained to
achieve hemostasis, i.e. a cessation or lessening of blood flow from a breach
or puncture in a
vein or artery, is subj ected to the size of the wound, the distance from the
skin surface, and
the amount of pressure applied in compressing the blood vessel. As used herein
in
connection with the invention, hemostasis means cessation of blood flow from a
breach or
puncture in a vein or artery. The amount of time for which compression is
maintained when
carrying out the methods of the invention is shorter in comparison to
compression alone or
compression without a composition of the invention as measured under
comparable
circumstances.
In general, when applying a manual compression technique it is preferable to
apply adequate but gradually lessening pressure for a period of time between
ten and thirty
minutes before inspection of the site, with reapplication of pressure as
necessary for ten to
twenty minute intervals (Camenzind et al, 1994, Journal of the American
College of
Cardiology. 24(3):655-662; Kipshidze et al., 1998, Journal of Invasive
Cardiology.
10(3):133-141; Sanborn et al., 1993, Journal of the American College of
Cardiology.
22(5):1273-1279). In certain instances, the period of time for which
compression is applied
may be greater than 30 minutes. If non-manual compression is employed in the
methods of
-18-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
the invention, then a constant pressure may be applied for ten to thirty
minutes or more,
particularly when applying compression alone. A technique corresponding to
stepwise
reduction in compression described above can be employed when using for
example a C-
clamp or compression bandage/dressing, wherein the pressure may be lessened in
increments
over time as necessary. A fluid-filled balloon connected to a pressure
transducer can also be
used to measure the amount of pressure applied. The amount of compression
force varies for
each patient and the type and location of the blood vessel, i.e. vein or
artery, being treated.
Any of the compression techniques described herein can be used in carrying out
the methods
of the invention, as well as other standard compression techniques.
In contrast, the time for applying compression, manual or otherwise, in
conjunction with a composition of the invention is shorter and may be divided
into intervals
at which to release or partially release pressure for 1-10 seconds in order to
record
observations to calculate the cessation rate or time of blood from a puncture
or breach and/or
to calculate the time to seal a puncture or breach. The time intervals may be
5, 10, 15, 20, 25,
30, 35, 40, 45, 50, 55, or 60 seconds in length. Alternatively, the time
intervals may be 1,
1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10
minutes in length (Silber et
al., 1998, Catheterization and Cardiovasular Diagnosis 43:421-427).
In a related embodiment, compression is applied for time intervals of
equivalent length in patients receiving the treatment compression alone and
those receiving
the treatment of compression in conjunction with the composition of the
invention.
In an embodiment, the decrease in the amount of time required to achieve
cessation or a decrease in blood flow from a breach or puncture in a vein or
artery using the
methods of the invention in comparison to using compression alone is
quantified as a
percentage.
Various methods for measuring compression time and compression force can
be employed in carrying out the methods of the invention as described in
section 5.2.4.
Compression should be applied to the desired vein or artery shortly following
the breach or puncture (or immediately following a breach or puncture caused
by a medical
procedure), or as soon possible in the case of accidental punctures or
breaches. For example
in one embodiment, caused by a medical procedure, compression is applied
immediately after
removal of a catheter and a catheter sheath.
-19-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
In a preferred embodiment of the invention, one or more of the methods
encompassed by the invention described herein are effective at achieving a
cessation or
reduction of blood flow out of a breach or puncture in an artery or vein in 3,
4, 5, 6, 7, 8, 9, or
minutes.
5 The compositions of the invention described herein in section S.5 are
preferably applied concurrently with an initial application of compression. In
other
embodiments, the compositions can be reapplied at compression time intervals.
In other
embodiments, compression is applied for a brief time prior to application of a
composition of
the invention and further compression.
10 5.2.4 MEASUREMENT OF TIME OR RATE OF CESSATION OF
BLEEDING OR SEALING OF BREACH OR PUNCTURE
In one embodiment, the rate or time of cessation or reduction of blood flow
from a breached or punctured blood vessel achieved using the present methods
can be
measured by any technique known to those skilled in the art. In certain
embodiments, for
example when testing the efficacy of the present compositions, the rate or
time of cessation or
reduction is measured and compared in the absence or presence of a composition
of the
invention. Preferably, the same technique is utilized when measuring the rate
or time of
cessation or reduction in the presence or absence of a composition of the
invention.
In certain embodiments, the efficacy of the compositions and methods of the
invention can be measured by simulating in dogs the cardiac catheterization
procedure used
in humans. The femoral artery in dogs is particularly desirable for such
simulations since it is
easily accessible, being located not far beneath the skin surface, and
hematomas can be easily
visualized in this region. Examples of cardiac catheterization simulations in
dogs and
determination in such dogs of rate or time of cessation of bleeding are
presented in Example
1 of Section 6. Measuring rate or time till cessation of blood flow from a
skin wound
contiguous with a breach or puncture in a vein or artery is an indirect
measurement of the
flow of blood from the breach or puncture in the vein or artery. Additional,
more direct,
techniques that can be used with the methods of the invention described herein
to observe
cessation of blood flow from the breach or puncture in the vein or artery are
taught below in
Section 5.3.
-20-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
The rate of or time to achieve cessation or reduction of blood flow out of the
breach or puncture in a vein or artery can be calculated simply as the total
number of time
intervals required to achieve the effect, provided the time intervals are
equivalent for each
treatment, i.e. compression alone or compression in conjunction with the
composition of the
invention. For example if the sum of the number of time intervals required for
all patients
receiving a first treatment is ~ and if the sum of number of time intervals
required for all
patients receiving a second treatment is 10, then the percent difference would
be 25%.
Alternatively, the average time to achieve cessation could be calculated for
each treatment
group, then compared to determine the percent difference.
In another embodiment, the time to achieve cessation is measured in minutes
and/or seconds rather than time intervals. The percent difference between the
times measured
can be calculated with one of the methods described above for the time
intervals method.
Where the time to achieve cessation of blood flow from the breach or puncture
in the vein or artery is are measured in minutes and/or seconds, the number of
time intervals
for which compression is applied may not necessarily be a factor in
calculating the time to
cessation. Total time from application of treatment to cessation or reduction
of blood flow
out of breached or punctured veins or arteries can be compared for the two
treatment groups.
In this embodiment of the invention, compression alone may be initially
applied for a longer
period of time than compression in conjunction with the composition of the
invention, since
values for the time to achieve cessation are known in the art for compression
alone. The time
to achieve cessation or the rate of cessation of blood flow from the breach or
puncture in the
vein or artery can also be measured for the circumstance where only
compression is applied.
These measurements can be made by any of the methods described herein,
including but not
limited to ultrasonography and scintigraphic imaging. For example, compression
alone may
be applied to a patient for 10 minutes before an observation is recorded,
while the patient
receiving compression in conjunction with the composition of the invention
would require
compression to be partially and briefly released to make blood flow
observations, in order to
obtain data to calculate the time to achieve cessation.
If a set number of compression timer intervals is applied, the percent
difference can be calculated based on the number of patients in each treatment
group. For
example, if compression is applied for two time intervals and 60 of 100
patients receiving a
first treatment consisting of compression alone achieve cessation of bleeding
from a breach
-21 -



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
or puncture or sealing of a breach or puncture in a vein or artery after two
compression
intervals, and 80 of 100 patients receiving a second treatment consisting of
compression plus
the composition of the invention achieve cessation or sealing of a breach or
puncture after
two equivalent time intervals, then the percent difference in time to achieve
hemostasis would
be 20%.
The rate of hematoma occurrence can be calculated with clinical observations.
One indicator of hematoma formation is swelling of the skin around the local
area of a
punctured or breached vein or artery. Alternatively, diagnoses of hematoma or
local vascular
complications as well as sealing and rates or time to achieve cessation of
blood flow from a
breach or puncture may also be made with various imaging techniques.
Statistical methodology can be employed to determine if the observed
differences are statistically significant. In particular, the differences
observed between the
rate of cessation or time to achieve cessation or occurrence of vascular
complications using
the methods of the invention in comparison to compression alone or compression
with
vasoconstrictors and/or coagulants that do not function at a distance can be
analyzed with
standard statistical methodology. Statistical significance can be determined
with any
standard calculated statistic (e.g., a one-tailed t-statistic, a two-tailed t-
statistic, a chi-square
statistic, an F-statistic, etc.). Standard statistical methodologies suitable
for use in connection
with the invention include methodologies commonly used in medical analyses and
clinical
trials. Examples of methodologies can be found in reference publications
including but not
limited to: Vogt W., 1998, Dictionary of Statistics and Methodology-2nd ed.,
SAGE
Publications; Spiegel, D., J. Myles, and K. R., 2002, Abrams Bayesian
Approaches to
Clinical Trials and Health Care: Statistics in Practice. Wiley, John & Sons,
Incorporated;
Cleophas, T. J., A. H. Zwinderman, and T. F. Cleophas, 2002, Statistics
Applied to Clinical
Trials-2nd ed., Gehan, E. A. A. and N. A. Lemalc, 1994, Kluwer Academic
Publishers; and
Statistics in Medical Research: Developments in Clinical Trials-1st ed.,
Kluwer Academic
Publishers.
In a preferred embodiment of the invention, the time to achieve cessation or
reduction of blood flow or the rate of cessation or reduction of blood flow
out of a breach or
puncture in the vein or artery is achieved at a greater rate or in less time
than applying
compression in conjunction with a topical barrier-forming material without a
vasoconstrictor
or coagulant, and without the formation of a hematoma. In another embodiment,
the time or
-22-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
rate of cessation or reduction of blood flow out of a breach or puncture in
the vein or artery is
achieved at a greater rate or in less time than applying compression in
conjunction with a
topical barrier-forming material without a vasoconstrictor or coagulant, and
the rate of
hematoma occurrence decreases.
For example, color flow duplex sonography of a puncture site can be used to
test for pseudoaneurysms, and AV fistulas (Gwechenberger et al, 1997,
Angiology.
48(2):121-126.) Scintigraphic Image Analysis can be employed to examine
bleeding andlor
hematoma formation at the site of breach or puncture and to determine if a
breach or puncture
is effectively sealed (Ismail et al., 1995, Catheterization and Cardiovasular
Diagnosis
34(1):88-95). Angiogram technology can also be used to examine sealing of a
breach or
puncture site (Hoekstra et al., 1998, Biomaterials. 19:1467-1471). With
imaging analyses as
described herein and in the examples section, the time or rate and percent
difference in rates
or times of cessation or reduction of blood flow out of a breach or puncture
in the vein or
artery can be calculated without releasing compression to make observations.
In embodiments where the femoral artery is punctured, distal pulse
measurements can be used to determine if effective closure of the puncture has
been
achieved. Similar techniques can be used on other arteries or veins.
In one aspect of the invention, the rate of cessation or reduction of blood
flow
out of a breach or puncture in the vein or artery when employing the methods
and
compositions of the invention is 10% greater than applying compression in
conjunction with
a topical barrier or gauze without a vasoconstrictor or coagulant. In a
related aspect of the
invention, the rate of cessation or reduction of blood flow out of a breach or
puncture in the
vein or artery when employing the methods and compositions of the invention is
10% greater
than applying compression in conjunction with a topical barrier or gauze
comprising less than
an effective amount of a vasoconstrictor. In other aspects, the rates as
described above are
10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80% or greater.
In one aspect of the invention, the time to achieve cessation or reduction of
blood flow out of a breach or puncture in the vein or artery when employing
the methods and
compositions of the invention is 10% less than applying compression in
conjunction with a
topical barrier or gauze without a vasoconstrictor or coagulant. In a related
aspect of the
invention, the time to achieve cessation or reduction of blood flow out of a
breach or
puncture in the vein or artery when employing the methods and compositions of
the invention
-23-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
is 10% less than applying compression in conjunction with a topical barrier or
gauze
comprising less than an effective amount of a vasoconstrictor. In other
aspects, the time as
described above is 10%, 15%, 20%, 25%, 30%, 35%, 40%; 45%, 50%, 60%, 70%, 80%
or
less.
In a preferred embodiment, the methods and compositions of the invention
effectively cause a cessation of blood flow from both a breach or puncture
site in a vein or
artery and from the wound site at the skin surface.
In a another preferred embodiment, the methods and compositions of the
invention effectively cause a cessation of blood flow from both a breach or
puncture site,
cause a cessation of blood flow from the wound site at the skin surface, and
decrease the
likelihood of localized vascular complications including hematoma formation.
5.2.5 SCINTIGRAPHIC IMAGE ANALYSIS
Scintigraphic Image Analysis can be employed to examine bleeding and/or
hematoma formation at site of breach or puncture and to determine if a breach
or puncture is
effectively sealed, especially in animal model systems (Ismail et al., 1995,
Catheterization
and Cardiovasular Diagnosis 34(1):88-95). For example if the invention is
being tested on
the femoral arteries of dogs, a camera fitted with a low energy all-purpose
collimator can be
placed in position over a puncture or breach site. Point sources (~50 uCi
99mTc) in suitable
containers may be used to record the exact position of the leg, for alignment
of subsequent
images. Dogs are injected through the external jugular venous cannula with
autologous
technetium-labeled red blood cells, (mean =16.65 ~ 3.51 mCi), for which the
labeling
efficiency is previously tested. The labeled cells are allowed to circulate
for 5 minutes before
images are taken. Images can be taken at regular time intervals up to 24
hours. Early images
can be used to ascertain sealing of a breach or puncture and cessation of
blood flow from the
breach or puncture, whereas later images can be used to identify hematomas
with great
efficiency.
5.2.6 ANGIOGRAPHY
An angiogram is a test in which a dye, or contrast, is administered to a
patient
and X-ray imaging is used to look inside blood vessels in order to diagnose or
treat lesions
-24-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
involving the blood vessels. Angiogram technology is commonly employed to
guide
catheters through the femoral artery in cardiac catheterization procedures
where the femoral
artery is punctured. Angiograms can also be used to examine, in a non-invasive
manner,
cessation of blood flow from a breach or puncture in a vein or artery, or
sealing of such a
breach or puncture (Hoekstra et al., 1998, Biomaterials. 19:1467-1471). CT or
MRI imaging
can also be used to examine sealing of a breach or puncture site and cessation
of blood from a
breach or puncture in a vein or artery.
5.2.7 ULTRASONOGRAPHY
Various sonography and ultrasonography techniques may be employed with
the methods and compositions of the invention to examine bleeding and/or
hematoma
formation at site of breach or puncture and to determine if a breach or
puncture is effectively
sealed. Figure 1 exemplifies another use of ultrasonography, determining the
distance
between the skin surface and an underlying vein or artery in a human. Duplex
ultrasonography has demonstrated useful clinical applications in peripheral
arterial testing for
lesion localization and quantification of abnormal blood flow. For example,
color flow
duplex sonography of a puncture site can be used to test for hematoma,
pseudoaneurysm, and
AV fistula formation (Gwechenberger et al, 1997, Angiology. 48(2):121-126).
5.2.8 THROMBOELASTOGRAPHY
Thromboelastography is a means of examining the whole process of blood
coagulation using whole blood. Thromboelastography is useful in connection
with the
present invention to determine time to cessation or reduction of blood flow
from a breached
or punctured vein or artery. In Thromboelastography measurments of time and
clot strength
are made. The results of the measurements are typically presented in a graph
representing the
beginning of clot formation to fibrinolysis. The graph represents the time
necessary for a clot
to form and the tensile strength of a clot. A clot has both viscous and
elastic properties,
however a thromboelastograph measures only the elastic properties of the clot.
Typically
clotting time is plotted on the x-axis and clot firmness or elasticity is
plotted on the y-axis.
The clotting time can be effected by various factors including clotting factor
deficiencies,
inhibitors, anticoagulants, and low platelets. Graphed measurements typically
result in an
-25-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
ovoid shape. The alpha angle is measured between the vertical midline of the
ovoid shape to
the beginning of clotting time. The alpha angle and the clot formation time
indicate how fast
the clot structure is forming, which can be effected by clotting factor
deficiencies, platelet
dysfunction, thrombocytopenia, hypofibrinogenaemia. Maximum clot firmness is
defined as
the width of the curve at the widest point. Maximum clot firmness can be
effected by low
platelets or low figbrinogen. Fibrinolysis is measured as a decrease in
amplitude from the
maximum. Typically a decrease of 15% or more is an indication that
fibrinolysis is taking
place. Examples of thromboelastographs that can be used in conjunction with
the claimed
invention include but are not limited to ROTEGTM, and TEG (Tromboelastography
Coagulation Analizer, Haemascope corporation, Niles, IL). A vasoconstrictor
and/or
coagulant of the invention can be examined by measuring the time to form a
clot and the
strength of a clot sealing a breach or puncture in a vein or artery with
thromboelastography.
The speed and strength of clotting can be used in determining if a breach or
puncture in a
vein or artery is effectively sealed.
5.2.9 ADMINISTRATION OF ANTICOAGULANTS
In certain embodiments of the invention, the methods and compositions of the
invention may be administered to a patient to whom an anticoagulant in an
effective amount
to prevent coagulation of blood has been administered. Examples of
anitcoagulants that may
be used in conjunction with the invention include, coumadinTM, dicumarolTM,
heparin,
nadroparin, aspirin, an antiplatelet drug, or a thrombolytic agent. Typically,
full dose of
heparinization for more than 12 hours before a medical procedure is common. In
other
protocols heparin is administered at repeated intervals to ensure that a
constant active clotting
time is maintained (Falstrom et al., 1997, Catheterization and Cardiovasular
Diagnosis 41:79-
~4). For those patients to whom an anticoagulant has been administered prior
to a puncture
or breach in a vein or artery, the composition of the invention may further
comprise one or
more agents that locally neutralize the effect of the administered
anticoagulant. In patients to
whom heparin has been administered the composition may further comprise
protamine
sulfate in an amount effective to locally neutralize heparin.
5.3 PHARMACEUTICAL COMPOSITIONS
-26-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
The present invention provides pharmaceutical compositions that can be used
in the practice of the methods of the invention. The pharmaceutical
compositions
encompassed by the present invention comprise an effective amount of one or
more
vasoconstrictors and/or one or more coagulants. The vasoconstrictors and/or
coagulants that
can be used in the methods of the invention can be any vasoconstrictor and/or
coagulant that
functions at a distance. The compositions of the invention can be formulated
into a wide
variety of shapes, sizes and masses. The compositions can additionally include
components
that have no known vasoconstrictive or coagulant properties.
As used herein, the term "effective amount" means a quantity of a
composition comprising a vasocontrictor andlor coagulant that can be applied
topically and
function, as a vasoconstrictor and/or a coagulant, at a distance to treat a
breach or puncture in
an artery or vein. The effectiveness of the amount can be measured by
comparing the time to
achieve or rate at which blood flow from a breach or puncture in a vein or
artery ceases or
slows in comparison to compression alone.
In certain embodiments of the invention, the compositions of the invention can
comprise combinations of agents in the methods of the invention. In one
embodiment, the
combination can comprise a vasoconstrictor and a coagulant. In other
embodiments, the
composition can comprise a greater quantity of vasoconstrictor than coagulant,
a greater
quantity of coagulant than vasoconstrictor. W yet other embodiments, the
compositions
comprise an agent that functions as both a vasoconstrictor and coagulant. The
term
"effective amount," as used herein, also means a total amount of a composition
of the
invention that is applied in the methods of the invention.
The size, shape, and mass of the composition used to topically treat a breach
or puncture in a vein or artery will vary depending on the particular use. A
pharmaceutical
composition can contain an effective amount of a vasoconstrictor, which unless
otherwise
indicated, does not comprise a poly-,Q-1-~ 4 N-acetylglucosamine polymer or
derivative
thereof. A pharmaceutical composition of the invention can also contain a
pharmaceutically
acceptable carrier.
As used herein derivatives of a poly-,Q-1-j 4 N-acetylglucosamine polymer
include: a semi-crystalline form of a poly-,Q-1~ 4 -acetylglucosamine polymer;
a
poly-(3-1-j 4 -acetylglucosamine polymer comprising about 50 to about 150,000
N-acetylglucosamine monosaccharides covalently attached in a ~3-1-j 4
conformation, and
-27-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
said polymer has a molecular weight of about 10,000 daltons to about 30
million daltons; a
poly-,Q-1-j 4 -acetylglucosamine polymer comprising about 50 to about 50,000
N-acetylglucosamine monosaccharides covalently attached in a (3-1-3 4
conformation, and
said polymer has a molecular weight of about 10,000 daltons to about 10
million daltons; a
poly-,Q-1-j 4 -acetylglucosamine polymer comprises about 50 to about 10,000
N-acetylglucosamine monosaccharides covalently attached in a (3-1~ 4
conformation, and
said polymer has a molecular weight of about 10,000 daltons to about 2 million
daltons; a
poly-~3-1-~ 4 -acetylglucosamine polymer comprising about 50 to about 4,000
N-acetylglucosamine monosaccharides covalently attached in a (3-1-j 4
conformation, and
said polyner has a molecular weight of about 10,000 daltons to about 800,000
daltons; and a
semi-crystalline poly-,Q-1-~ 4 N-acetylglucosamine polymer comprising at least
one
N-acetylglucosamine monosaccharide that is deacetylated, and wherein at least
40% of said
N-acetylglucosamine monosaccharides are acetylated.
Derivatives of a poly-,Q-1-j 4 N-acetylglucosamine polymer also include
compositions that are 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10% or
less
poly-,Q-1--~ 4 N-acetylglucosamine. Thus, with varying degrees of purity of a
vasoconstrictor
and/or coagulant is encompassed by the invention.
In certain embodiments of the invention, the composition of the invention
comprises a vasoconstrictor and/or a coagulant with one of more of the
following provisos
that the composition of the invention does not comprise in certain
embodiments:
1. The composition of the invention does not comprise a poly-(3-1-j 4 N-
acetylglucosamine polymer or derivative thereof. The composition does not
comprise a
poly-,Q-1-~ 4 N-acetylglucosamine polymer or derivative thereof and an agent
that functions
as a vasoconstrictor and/or coagulant
2. The composition of the invention does not comprise a poly-a 1-j 4 N-
acetylglucosamine polymer or derivative thereof. The composition does not
comprise a
poly-a-1-j 4 N-acetylglucosamine polymer or derivative thereof and an agent
that functions
as a vasoconstrictor and/or coagulant
3. The composition of the invention does not comprise a poly-a 1-j 4 N-
acetylglucosamine polymer or derivative thereof and a poly-~i-1-j 4 N-
acetylglucosamine
polymer or derivative thereof. The composition does not comprise a poly-a 1~ 4
N
-28-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
acetylglucosamine polymer or derivative thereof, poly-(3-1-3 4 N-
acetylglucosamine polymer
or derivative thereof, and an agent that functions as a vasoconstrictor and/or
coagulant
4. The composition of the invention does not comprise chitosan, a
chitosan derivative, or compositions natural or synthetic that comprise 10%-
100% chitosan or
a chitosan derivative. The composition of the invention does not comprise
chitosan or a
chitosan derivative derived from crustaceans. The composition of the invention
does not
comprise chitosan or a chitosan derivative derived from crustaceans wherein
the chitosan or a
chitosan derivative have been purified or modified.
5. The composition does not comprise chitosan or a chitosan derivative
that is 80% or more deacetylated. The composition does not comprise chitosan
or a chitosan
derivative that is 70%-100% deacetylated.
6. The composition does not comprise chitosan or a chitosan derivative
that is free of fungal, micro-fungal, and crustacean chitosan or chitosan
derivatives.
7. The composition of the invention does not comprise chitin, a chitin
derivative, or compositions natural or synthetic that comprise 10%-100% chitin
or a chitin
derivative. The composition of the invention does not comprise chitin or a
chitin derivative
derived from crustaceans. The composition of the invention does not comprise
chitin or a
chitin derivative derived from crustaceans wherein the chitin or a chitin
derivative have been
purified or modified.
8. The composition does not comprise chitin or a chitin derivative that is
80% or more deacetylated. The composition does not comprise chitin or a chitin
derivative
that is 70%-100% deacetylated.
9. The composition does not comprise chitin or a chitin derivative that is
free of fungal, micro-fungal, and crustacean chitin or chitin derivatives.
10. The composition does not comprise one or more coagulants, for
example: alpha-2-antiplasmin, alpha-1-antitrypsin, alpha-2-macroglobulin,
aminohexanoic
acid, aprotinin, a source of Calcium ions, calcium alginate, calcium-sodium
alginate, casein
lcinase II, chitin, chitosan, collagen, cyanoacrylates, epsilon-aminocaproic
acid, Factor XIII,
fibrin, fibrin glue, fibrinogen, fibronectin, gelatin, living platelets, metha
crylates, PAI-1,
PAI-2, plasmin activator inhibitor, plasminogen, platelet agonists, protamine
sulfate,
prothrombin, an RGD peptide, sphingosine, a sphingosine derivative, thrombin,
thromboplastin, and/or tranexamic acid.
-29-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
11. The composition does not comprise epinephrine.
In certain embodiments of the invention, the composition of the invention
comprises a vasoconstrictor and/or a coagulant with one of more of the above
provisos in
certain embodiments.
In one embodiment, compositions of the invention encompass purified
vasoconstrictors and/or coagulants, which may be about 100%, 90%, 80%, 70%,
60%, 50%,
40%, 30%, or 20% pure. In a related embodiment, compositions of the invention
encompass
purified vasoconstrictors and/or coagulants, which range between 100% and 20%
in purity.
In a preferred embodiment, the vasoconstrictors and/or coagulants is 90-100%
purified. In
another embodiment, the composition can consist of approximately 100%, 90%,
80%, 70%,
60%, 50%, 40%, 30%, 20%, 10% or less of a vasoconstrictor or coagulant. In a
related
embodiment, the composition can consist of between 100%, and 10% or less of a
vasoconstrictor or coagulant. Thus, the use of a vasoconstrictor and/or
coagulant with
varying degrees of purity is encompassed by the invention.
Vasoconstrictors and/or coagulants that function at the desired distance can
be
identified using the methods described herein. For example, the cardiac
catheterization
procedure simulation in dogs described in Example 1, of Section 6 can be used
to measure
the effect of potential vasoconstrictors and/or coagulants at varying
distances. The only
portion of the procedure that needs to actually be simulated is the puncture
of a vein or artery
with a catheter, mechanical observation or manipulation to observe the
vasculature associated
with the heart is not necessary. The identification of vasoconstrictors and/or
coagulants that
function at varying distances can be achieved by selecting veins or arteries
at specific
distances beneath the skin surface for catheter puncture. The distance of such
veins or
arteries can be determined by imaging techniques such as those disclosed in
Section 5.2.
The composition can be formulated as a gel, solid, liquid, sponge, foam,
spray,
emulsion, suspension, solution, string, microbead, microsphere, or
microfibril. The
pharmaceutical compositions of the invention can include a pharmaceutically
acceptable
carrier, a neutral liquid, neutral gel or neutral solid. In certain preferred
embodiments,
wherein the composition has been formulated as a barner, membrane, or film or
the
composition has been added to a barrier, membrane, or film, the neutral solid
or solid
composition can be provided as a barrier, membrane, or film. A barrier,
membrane, or film
can be supplied in a variety of standard sizes, which can be further cut and
sized to the area
-30-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
being treated. The barner, membrane, or film can be a conventional bandage or
gauze to
which the composition of the invention is added or coated on, prior to
application to the
patient. Alternatively, the composition can be formulated as a barrier,
membrane, or film
made out of strings, microbeads, microspheres, or microfibrils, or the
composition can be
formulated as a barrier-forming mat.
The pharmaceutical compositions of the invention can include a backing. For
example, if the composition is formulated as a patch, a backing can be adhered
to the patch.
The backing can be coated or embedded with any adhesive compound so that areas
of the
backing that contact the skin will adhere the backing and the attached
composition of the
invention to the skin surface of the patient. The type of adhesive used can be
any type of
medically acceptable adhesive. Such backings can be made of natural polymers
or synthetic
materials. Natural polymers from which the backing can be made include but are
not limited
to cellulose and xylan. Synthetic materials from which the backing can be made
include but
are not limited to polyurethane, Teflon, Dacron, stainless steel mesh screen,
and a polyester
woven fabric. Preferably the backing and adhesive are porous to areas which
contact the shin
to allow diffusion of oxygen. The backing can also serve as a surface upon
which manual
compression can be applied.
The composition may be formulated as a barrier-forming material that forms a
barrier to blood. The composition can coat, be added to, or integrated into a
barrier-forming
material that forms a barrier to blood. In one embodiment ,the pharmaceutical
composition
comprises a patch made of barrier-forming materials that are embedded with one
or more
coagulant and/or vasoconstrictor agent(s). In one embodiment, the
pharmaceutical
composition comprises a gauze embedded with one or more coagulant and/or
vasoconstrictor
agent(s). In certain embodiments, the pharmaceutical compositions comprise a
barrier-
forming material embedded or combined with one or more coagulant and/or
vasoconstrictor
agent(s), wherein the barrier-forming material contains an adhesive so that
the material can
be adhere to a patient's skin surface. Alternatively, the composition can lack
barner-forming
materials.
According to one aspect of the invention, where the composition is formulated
as or applied or integrated in a patch, the patch may vary in size. For
example, the patch may
be about 2 cmz to about 30 cm2 in area. In certain embodiments, the patch is
round, square,
or rectangular. In preferred embodiments, the patch is 2 cm x 2 cm, 3 cm x 3
cm, 4 cm x 4
-31-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
cm, 5 cm x 5 cm, or 6 cm x 6 cm in size. In other preferred embodiments, the
patch can be
cut to reduce the size or to create a two dimensional shape as needed. In
preferred
embodiments, the above described patches can be manufactured for use in the
methods,
compositions, and kits of the invention for adult patients weighing about 60,
70, 80, or 90 kg.
In related embodiments, the composition of the invention can contain collagen
that can act as a sterile carrier.
In a preferred embodiment, the composition may include one or more
coagulants. The coagulant(s), for example, can be one or more of the
following: alpha-2-
antiplasmin, alpha-1-antitrypsin, alpha-2-macroglobulin, aminohexanoic acid,
aprotinin, a
source of Calcium ions, calcium alginate, calcium-sodimn alginate, casein
kinase II, chitin,
chitosan, collagen, cyanoacrylates, epsilon-aminocaproic acid, Factor XIII,
fibrin, fibrin glue,
fibrinogen, fibronectin, gelatin, living platelets, metha crylates, PAI-1, PAI-
2, plasmin
activator inhibitor, plasminogen, platelet agonists, protamine sulfate,
prothrombin, an RGD
peptide, sphingosine, a sphingosine derivative, thrombin, thromboplastin, and
tranexamic
acid.
In related embodiments, the composition of the invention can contain an anti-
fungal or antibacterial agent, to prevent infection of the wound surrounding
the breach or
puncture in the vein or artery.
In a preferred embodiment, the composition may include one or more
vasoconstrictors. The vasoconstrictor(s), for example, can be one or more of
the following:
endothelin, endothelin-1, epinephrine, adrenaline, metaraminol bitartrate (for
example,
manufactured as AramineTM), dopamine HCl (for example, manufactured as
IntropineTM),
isoproterenol HCl (for example, manufactured as IsuprelTM), norepinephrine
(for example,
manufactured as LevophedTM), phenylephrine, serotonin, thromboxane,
norepinephrine,
prostaglandin, methergine, oxytocin, isopreland U-46619, papaverine,
yohimbine, visnadin,
khellin, bebellin, and nicotinate derivatives.
hi certain embodiments, the composition comprises a catalytic surface that
accelerates a rate of a chemical reaction between the composition of the
invention and
endogenous agents involved in hemostasis. The catalytic surface decreases the
time to
hemostasis and decreases the time to achieve cessation or reduction of blood
flow from the
breach or puncture in the vein or artery. The catalytic surface binds blood
components to
form a plug. The catalytic surface comprises a catalyst that is active at a
distance, a distance
-32-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
as described herein in the context of the invention. The catalyst can reduce
hemostasis time
by causing rapid release of vasoconstrictors substances and/or increasing the
concentration of
vasoconstrictor substances. In other embodiments, the composition comprises a
catalytic
surface that accelerates a rate of a chemical reaction between endogenous
agents involved in
hemostasis, such as the conversion of fibrinogen to fibrin. In yet other
embodiments, the
composition comprises a catalytic surface that accelerates or inhibits
endogenous processes
involved in hemostasis, such as release of serotonin by platelets or release
of prothrombin or
chemical signals by damaged tissues. The chemical reaction or cellular process
may be
involved with vascular constriction that normally follows injury to a blood
vessel such as
platelet plug formation, i. e. adherence of platelets to the exposed basement
membrane and
connective tissue, change in shape of platelets from their discoid shape,
secretion of ADP,
secretion of serotonin, secretion of phospholipid, synthesis of platelet
factors, activation of
phospholipase C, liberation of Calcium ions, activation of phospholipase A2,
liberation of
arachidonic acid, secretion of plasma clotting factors. The compositions of
the invention can
increase nucleation and formation of clots and/or the phase transition of
blood components
from liquid to solid during the formation of a clot.
In one embodiment, the catalytic surface comprises fibers that are
undissolveable and which are woven into a mat.
~ In certain embodiments, the compositions of the invention comprise
vasoconstrictors and/ or coagulants that are evenly distributed throughout the
composition, or
supplied as a gradient, for example, by combining fibrous pulps containing a
range of desired
concentrations of vasoconstrictors and/ or coagulants to produce a
multilayered composition.
The composition of the invention can contain a biodegradable material.
Examples of biodegradable materials which can be used in the composition of
the invention
include polyanionic polysaccharides, alginic acid, collagen, polyglycolide,
polylactide,
polycaprolactone, dextran and copolymers thereof, polyglycolide, polylactide,
polydioxanones, polyestercarbonates, polyhydroxyalkonates, polycaprolactone,
and
copolymers thereof. Such biodegradable materials may form a barrier-forming
portion of the
composition, or act as Garners.
The pharmaceutical compositions of the invention can also comprise wound-
healing and/or pain-reducing agents. Such agents include anti-inflamatory
agents, both
steroidal and non-steroidal, such as but not limited to agents which inhibit
leukocyte
-33-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
migration into the area of the breach or puncture in the blood vessel (i.e.,
silver sulfadiazinem
acetylsalicylic acid, indomethacin, and Nafazatrom), anti-histamines (i.e.,
pyrilamine,
chlorpheniramine, tetraydrozoline, antazoline, cortisone, hydrocortisone, beta-
methasone,
dexamethasone, fluocortolone, prednisolone, triamcinolone, indomethacin, and
sulindac, its
salts and its corresponding sulfide); agents which inhibit free radical
formation (i.e.,
superoxide dismutase (SOD), catalase, glutathione peroxidase, ~3-carotene,
ascorbic acid,
transferring, ferritin, ceruloplasmin, and desferrioxamine alpha-tocophenol);
and
bacteriostatic or bacteriocidal agents (i. e., cefoxitin, n-formamidoyl
thienamycin, tetra
cyclines, chloramphenicol, neomycin, gramicidin, bacitracin, sulfonamides,
gentarnycin,
kanamycin, amikacin, sisomicin, tobramycin, norfloxican, nitrofurazones, and
the
combination of flouroalaninlpentizidone).
5.4 EFFECTIVE DOSE
Generally, a therapeutically effective amount of a vasoconstrictor and/or
coagulant for use in the methods, compositions, and kits of the invention,
will vary with the
patients age, condition, and sex, as well as the nature and extent of the
condition in the
subj ect, all of which can be determined by one of ordinary skill in the art.
For example, the
effective dose needed for an infant may differ from an elderly patient, due to
the reduced
elasticity of blood vessels that accompanies age. The effective dose can also
be dependent on
the depth beneath the skin surface at which a breach or puncture in a blood
vessel is being
treated. The dosage of the vasoconstrictor and/or coagulant of the invention
can be adjusted
to accommodate the particular subject and condition being treated.
In certain embodiments, the effective amount of the vasoconstrictor and/or
coagulant does not directly increase or decrease the function of cells
involved in wound
healing such as but not limited to polymorphonuclear leukocytes, macrophages
and
fibroblasts.
Toxicity and efficacy of the vasoconstrictor and/or coagulant of the invention
can be determined by standard pharmaceutical procedures in cell cultures or
experimental
animals, e.g., for determining the ED50 (the dose therapeutically effective in
50% of the
population). Vasoconstrictors and/or coagulants that exhibit greater
therapeutic effect are
preferred. In the present instance, vasoconstrictors and/or coagulants that
exhibit toxic side
-34-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
effects may be used in carrying out the methods of the invention. The
potential damage to
unaffected cells is minimized, since the vasoconstrictors and/or coagulants
are applied to the
site of affected tissue and thereby reduce the risk of side effects.
The data obtained from the cell culture assays and animal studies can be used
in formulating a range of dosage for use in humans. The dosage of such
vasoconstrictors
and/or coagulants lies preferably within a range of concentrations that
include the ED50. The
dosage may vary within this range depending upon the formulation of the
composition, i.e.,
gel, foam, patch, etc. For any vasoconstrictor used in the method of the
invention, the
therapeutically effective dose can be estimated initially from tissue or
tissue culture assays.
One standard tissue assay is conducted using aortic rings excised from rats.
The aorta are then rapidly suspended in a warmed Krebs- Henseleit (KH) buffer
consisting of
(in mmol/1): 118 NaCI, 4.75 KCI, 2.54 CaCI2.2H20, 1.19 KHZP04, 1.19MgS04.7H20,
12.5
NaHC03, and 10.0 glucose. Isolated vessels can be carefully freed of
connective tissue and
cut into rings 2-3 mm in length. The rings are then mounted on stainless steel
hooks,
suspended in a 10-ml tissue bath, and connected to FT-03 force displacement
transducers
(Grass Instrument, Quincy, MA) to record changes in force on a Grass model 7
oscillographic
recorder. The baths are filled with KH buffer and aerated at 37°C with
95% OZ + 5% C02. A
resting force of 0.5 g is applied to the SMA rings, and then the rings are
equilibrated for 90
minutes. During this period, the buffer in the tissue bath is replaced every
15-20 minutes,
and the resting force of the vascular rings is adjusted until 0.5 g of pre-
load is maintained.
After 90 to 120 minutes of equilibration, the rings are exposed to 100nM U-
46619 (9,11-
dideoxy-9a 11 a methaneepoxy-prostagalandin FZ «, Biomol Research
Laboratories, Plymouth
Meeting, PA), a thromboxane AZ mimetic, to generate 1.0 g of developed force.
Once a
stable contraction is obtained, acetylcholine, a typical endothelium-dependent
vasodilator, is
added to the bath in cumulative concentrations of 0.1, 1, 10, and 100nM to
assess the
integrity of endothelium. After the cumulative response is stabilized, the
rings are washed
and again allowed to equilibrate to baseline.
This procedure can be used with a vasoconstrictor other than U-46619 to
determine the effectiveness of a vasoconstrictor at maintaining
vasoconstriction. The
procedure can be repeated with varying concentration of a vasoconstrictor to
determine
effective dosage.
-35-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
The function of a coagulant can be tested by standard assays. In such assays,
normal human blood, without anticoagulant, is drawn and placed in several test
tubes. The
normal blood, without a composition of the invention, is allowed to clot
(usually within 10
minutes). Other samples of normal blood are drawn and one milliliter aliquots
are placed in
test tubes with descending aliquots of a particular coagulant used in the
methods,
compositions, and kits of the invention for which one desires to test
coagulant properties.
With such an assay one can readily determine how many tenths of a milliliter
of the coagulant
are effective at causing clotting at a greater rate or in less time than blood
without a
coagulant. Variations on this standard assay can be conducted where the
patient has had an
anticoagulant introduced into the bloodstream prior to withdrawal of blood.
The results can
be used to identify coagulant for use in the methods, compositions, and kits
of the invention
that can accelerate hemostasis, i. e. cessation of flow of blood from a breach
or pmcture in a
vein or artery.
In various embodiments, an amount of vasoconstrictor and/or coagulant used
in the methods, compositions, and kits of the invention is an amount that is
0.5-fold, 0.75-
fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 12-fold, 15-fold, 20-
fold, 50-fold or 100-
fold the effective dosage, for example, the dosage determined to be effective
in treating a
breach or puncture in a vein or artery when applied at a distance from the
breach or puncture.
The vasoconstrictors and/or coagulants can be formulated into solid, liquid or
gel-type formulations for topical application. The concentration of
vasoconstrictor and/or
coagulants in solid, liquid and/or gel-type formulations can be extrapolated
from the dosage
and the volume or surface area of the formulation to be applied. For example,
such
compositions can be manufactured for general use for adults, e.g., adults
weighing about 50,
60, 70, 80, or 90 kg, and a topical administration area, e.g., of a patch, of
about 1-2, 2-4, 4-8,
8-12, 12-15, 15-20, 20-25, or 25-30 cma, or a topical administration volume,
e.g., of a liquid
or gel, of about 0.25-0.5, 0.5-1, 1-1.25, 1.25-1.5, 1.5-1.75, 1.75-2, 2-2.5,
or 2.5-3 ml.
Exemplary concentration calculations are provided in Section 5.4.1, inf-a.
In embodiments of the invention where the composition of the invention is
formulated as, embedded in, or applied to a patch, 100 mg of the
vasoconstrictor and/or
coagulant may be present in 1 cm2 of the wound-contacting surface of the
patch. In other
embodiments, the effective amount of a vasoconstrictor and/or coagulant for
use in the
methods, compositions, and kits of the invention present in 1 cm2 of a patch
can be about
-36-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
0.05 mg, 0.10 mg, 0.25 mg, 0.50 mg, 0.75 mg, 1 mg, 2 mg, 5 mg, 8 rng, 10 mg,
15 mg, 20
mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75
mg, 80
mg, 85 mg, 90 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450
mg, 500
mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 1000 mg,
or 2000
mg. IIi a preferred embodiment, the effective amount of a vasoconstrictor
and/or coagulant of
the invention present in 1 cma of a patch is between 0.05 mg and 30 mg of the
vasoconstrictor
and/or coagulant.
In other embodiments, where the vasoconstrictor and/or coagulant of the
invention is formulated as, embedded in, or applied to a patch, 100 ~.g of the
vasoconstrictor
and/or coagulant may be present in 1 cm2 of the wound-contacting surface of
the patch. In
other embodiments, the effective amount of a vasoconstrictor and/or coagulant
of the
invention present in 1 cm2 of a patch can be about 5 ~,g, 10 ~,g, 20 ,ug, 25
~,g, 30 ~,g, 35 ~,g, 40
~,g, 45 ,ug, 50 fig, 55 ~,g, 60 ~,g, 65 ~,g, 70 ~,g, 75 ~,g, 80 ~.g, 85 ~.g,
90 ~.g, 95 ~,g, 100 ,ug, 105
~,g, 110 ~.g, 115 ~,g, 120 ~.g, 125 ~.g, 130 ,ug, 135 ~,g, 140 ,ug, 145 ,ug,
150 ,ug, 155 ~Cg, or 160
~.g between about 1mM and 70mM. An example of a coagulant that can be
effective in such
amounts is thrombin. An example of a vasoconstrictor that can be effective in
such amounts
is endothelin-1.
hi preferred embodiments of the present methods and compositions, the dose
of a vasoconstrictor and/or coagulant, e.g., on the surface of a patch,
regardless of its
molecular weight, is about 1mM to about 70 mM. hi certain exemplary
embodiments, the
dose is about 1mM to about 10 mM, about lOmM to about 30 mM, about 30 mM to
about 50
mM, or about 50 mM to about 70 mM.
In yet other embodiments, the effective amount of a vasoconstrictor and/or
coagulant of the invention is about 1-1000 IU/cmz wherein the vasoconstrictor
and/or
coagulant is formulated as, embedded in, or applied to a patch.
In one embodiment, the vasoconstrictor and/or coagulant forms a
concentration gradient that decreases from the site of application to the
breach or puncture in
the vein or artery. For example, in the case of a cardiac catheterization
track wound, the
vasoconstrictor and/or coagulant can form a concentration gradient through the
track wound
and promote clot formation throughout the track resulting in an decreased in
the time
necessary to achieve hemostasis.
-37-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
In certain embodiments, an effective amount of a vasoconstrictor and/or
coagulant of the invention is an amount that activates hemostasis in the
presence of a
coagulant or an anticoagulant.
In certain embodiments, the effective dose is the dose necessary to initiate
clotting with or without compression. In other embodiments, the effective dose
is the dose
necessary to cause formation of a firm clot that will remain with or without
compression. In
yet other embodiments, an effective dose can be determined by the strength of
the clot, i.e.
the time for which the clot holds with or without compression.
Once it has been determined how varying concentrations and amounts of a
particular vasoconstrictor and/or coagulant act i~ vitro, effective
vasoconstrictors and/or
coagulants can be further tested in animal models for the distance at which
they function by
methods described in Section 5.5. An effective amount of a vasoconstrictor
and/or coagulant
that functions at a given distance can be determined by measuring the time to
form a clot and
the strength of a clot sealing a breach or puncture in a vein or artery with
thromboelastography. A series of measurements can be taken varying the
concentration or
amount of the vasoconstrictor and/or coagulant to determine an effective
amount. The
distance of a breach or puncture in a vein or artery from the skin surface can
also be varied to
determine the maximum or optimal effective distance. Such series of
measurements can be
used to predict how a particular vasoconstrictor and/or coagulant will
function at a particular
distance, and allow for a determination of effective amount for a desired
distance. The
distance animal veins or arteries are beneath the skin surface can be
determined by imaging
techniques such as those disclosed in Section 5.4. The distance at which
certain
concentrations or amounts of vasoconstrictors and/or coaguhants are effective
ira vivo can be
used to extrapolate the effective amount for a desired distance needed for a
particular patient,
or the limit to the distance at which a particular vasoconstrictor and/or
coagulant is effective.
Such information can be used to more accurately determine useful doses in
humans.
Results from animal models can be extrapolated to determine effective doses
for human subjects. Comparing varying concentrations of a vasoconstrictor
and/or coagulant
in one or more animal models allows for the establishment of dose response
curves that can
be used to estimate effective amounts in a human, given the particular
circumstances of each
subj ect, i. e. distance of wound, size of wound, presence of coagulants or
anticoaguhants in the
blood stream.
-3~-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
Human patients can also be used to determine the distance at which a
vasoconstrictor and/or coagulant is effective. For example, ultrasound can be
used to
visualize the distance a breach or puncture in a vein or artery is from the
surface of the skin
and determine if blood flow from the breach or puncture has decreased or been
eliminated.
Ultrasound probes can be used to locate the breached or punctured vein or
artery or to image
a specific area by aligning the probes with a desired vein or artery.
Ultrasound imaging of
the breach or puncture site can be combined with Doppler flow analysis.
Doppler flow
analysis allows for the determination of cessation or reduction of blood flow
through the
artery or vein. If blood flow through the vein or artery is inhibited, it may
cause damage.
Thus, combining Doppler flow and ultrasound would allow for a determination of
the
maximum upper limit of an effective amount of a vasoconstrictor and/or
coagulant. For
example, if the effect of a coagulant extends into the blood vessel and causes
clotting of
platelet and cessation of blood within the blood vessel, the effect could be
damaging. In
another embodiment, the maximum upper limit of an effective amount of a
vasoconstrictor
and/or coagulant can be measured as the amount of the vasoconstrictor and/or
coagulant for
use in the methods, compositions, and kits of the invention that causes an
increase in cardiac
output.
5.4.1 VASOCONSTRICTOR DOSES
In certain preferred embodiments, the effective amount of a vasoconstrictor
used in the compositions of the methods, compositions, and kits of the
invention will vary
with the patients age, condition, and sex, as well as the nature and extent of
the condition in
the subject, all of which can be determined by one of ordinary skill in the
art. For example, a
patients body weight can be used to determine an effective amount of a
vasoconstrictor.
In one embodiment, the composition topically administered to a patient in the
methods of the invention comprises an effective amount of the vasoconstrictor
AdrenalineTM
in a concentration in the range of about 0.000001 mg/kg of patient body weight
to about 11
mg/kg of patient body weight. For adults the preferred AdrenalineTM
concentration range is
about 0.00001 mg/lcg to about 0.5 mg/kg. In related embodiments the effective
amount of
AdrenalineTM is approximately 0.00001 mg/kg, 0.00005 mg/kg, 0.0001 mg/lcg,
0.0005 mg/kg,
0.001 mg/kg, 0.005 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mglkg, 0.5 mg/kg, 1.0
mg/kg, 1.5
-39-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
mg/kg, 2.0 mg/kg, 2.5 mglkg, 3.0 mg/kg, 3.5 mg/kg, 4.0 mg/kg, 4.5 mg/kg, 5.0
mg/kg, 5.5
mg/kg, 6.0 mg/kg, 6.5 mg/kg, 7.0 mg/kg, 7.5 mg/kg, 8.0 mg/kg, 8.5 mg/kg, 9.0
mg/kg, 9.5
mg/kg, 10.0 mg/kg, 10.5 mg/kg, or 11.0 mg/kg of patient body weight. In
related
embodiments the effective amount of AdrenalineTM is about 0.00001 mg/kg to
0.0001 mg/kg,
0.001 mg/kg to 0.01 mg/kg, 0.1 mg/kg to 1.0 mglkg, 2.0 mg/kg to 3.0 mg/kg, 4.0
mg/kg to
5.0 mg/kg, 6.0 mg/kg to 7.0 mg/kg, 8.0 mg/kg to 9.0 mg/kg, or 10.0 mg/kg to
11.0 mg/kg of
patient body weight. In related embodiments the effective amount of
AdrenalineTM is about
0.00005 mg/kg to 0.0005 mg/kg, 0.005 mg/kg to 0.05 mg/kg, 0.5 mg/kg to 1.5
mg/kg, 2.5
mglkg to 3.5 mg/kg, 4.5 mg/kg to 5.5 mg/kg, 6.5 mg/kg to 7.5 mg/kg, 8.5 mg/kg
to 9.5
mg/kg, or 10.5 mg/kg to 11.5 mg/kg of patient body weight
In another embodiment, the composition topically administered to a patient in
the methods of the invention comprises an effective amount of the
vasoconstrictor
metaraminol bitartrate in a concentration in the range of about 0.00001 mg/kg
of patient
body weight to about 1500 mg/kg of patient body weight. For adults the
preferred
metaraminol bitartrate concentration range is about 0.0005 mg/kg to about 4.5
mg/kg. In
related embodiments the effective amount of metaraminol bitartrate is
approximately 0.0005
mg/kg, 0.001 mg/kg, 0.005 mg/kg, 0.01 mglkg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg,
1.0
mg/kg, 10 mg/kg, 50 mg/kg, 100 mg/kg, 150 mg/kg, 200 mg/kg, 300 mg/kg, 400
mg/kg, 500
mg/kg, 600 mg/kg, 700 mg/kg, 800 mg/kg, 900 mglkg, 1000 mg/kg, 1100 mg/kg,
1200
mg/kg, 1300 mg/lcg, 1400 mg/kg, or 1500 mg/kg of patient body weight. In
related
embodiments the effective amount of metaraminol bitartrate is about 0.0005
mg/kg to 0.005
mg/kg, 0.05 mg/kg to 0.5 mg/kg, 50 mg/kg to 150 mg/kg, 300 mg/kg to 500 mg/kg,
700
mg/kg to 900 mg/kg, 1100 mg/kg to 1300 mg/kg, or 1300 mg/kg to 1500 mg/kg of
patient
body weight. In related embodiments the effective amount of metaraminol
bitartrate is about
0.001 mg/kg to 0.01 mg/kg, 0.1 mg/kg to 1.0 mg/kg, 10 mg/kg to 100 mg/kg, 200
mg/lcg to
400 mg/kg, 600 mg/kg to 800 mg/kg, 1000 mglkg to 1200 mg/kg, or 1200 mg/kg to
1400
mg/kg of patient body weight.
In one embodiment, the composition topically administered to a patient in the
methods of the invention comprises an effective amount of the vasoconstrictor
dopamine HCl
in a concentration in the range of about 0.00001 mg/kg of patient body weight
to about 150
mg/kg of patient body weight. For adults the preferred dopamine HCl
concentration range is
about 0.0005 mg/kg to about 10 mg/kg. In related embodiments the effective
amount of
-40-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
dopamine HCl is approximately 0.0005 mglkg, 0.001 mg/kg, 0.005 mg/kg, 0.01
mg/kg, 0.05
mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, 40
mg/kg, 50
mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/lcg, 110 mg/kg, 120
mg/kg, 130
mg/kg, 140 mg/kg, or 150 mg/kg of patient body weight. In related embodiments
the
effective amount of dopamine HCl is about 0.0005 mg/kg to 0.005 mg/kg, 0.05
mg/kg to 0.5
mg/kg, 10 mg/kg to 30 mg/kg, 50 mg/kg to 70 mg/kg, 90 mg/kg to 110 mg/kg, or
130 mg/kg
to 150 mg/kg of patient body weight. In related embodiments the effective
amount of
dopamine HCl is about 0.001 mg/kg to 0.01 mg/kg, 0.1 mg/kg to 1.0 mg/kg, 10
mg/kg to 20
mg/kg, 40 mg/kg to 60 mg/kg, 80 mg/kg to 100 mg/kg, or 120 mg/kg to 140 mg/kg
of patient
body weight.
In one embodiment, the composition topically administered to a patient in the
methods of the invention comprises an effective amount of the vasoconstrictor
isoproterenol
HCl in a concentration in the range of about 0.00001 mg/kg of patient body
weight to about
150 mg/kg of patient body weight. For adults the preferred isoproterenol HCl
concentration
range is about 0.0005 mg/kg to about 5 mg/kg. In related embodiments the
effective amount
of isoproterenol HCl is approximately 0.0001 mg/kg, 0.0005 mg/kg, 0.001 mg/kg,
0.005
mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 10 mg/kg, 20
mg/kg, 30
mg/kg, 40 mg/kg, 50 mg/kg, 60 mglkg, 70 mglkg, 80 mg/kg, 90 mg/kg, 100 mg/kg,
110
mg/kg, 120 mg/kg, 130 mg/lcg, 140 mg/kg, or 150 mg/kg of patient body weight.
In related
embodiments the effective amount of isoproterenol HCl is about 0.0001 mg/kg to
0.001
mg/kg, 0.01 mg/kg to 0.1 mg/kg, 1.0 mg/kg to 20 rnglkg, 40 mg/kg to 60 mg/kg,
80 mg/kg to
100 mg/kg, or 120 mg/kg to 140 mg/kg of patient body weight. In related
embodiments the
effective amount of isoproterenol HCl is about 0.0005 mg/kg to 0.005 mg/kg,
0.05 mg/kg to
0.1 mg/kg, 0.5 mg/lcg to 10 mg/kg, 30 mg/kg to 50 mg/kg, 70 mglkg to 90 mg/kg,
110 mg/kg
to 130 mg/kg, or 130 mg/kg to 150 mg/kg of patient body weight.
In one embodiment, the composition topically administered to a patient in the
methods of the invention comprises an effective amount of the vasoconstrictor
norepinephrine in a concentration in the range of about 0.00001 mg/kg of
patient body
weight to about 2 mg/kg of patient body weight. For adults the preferred
norepinephrine
concentration range is about 0.0001 mg/kg to about 0.01 mg/kg. In related
embodiments the
effective amount of norepinephrine is approximately 0.0001 mg/kg, 0.0005
mg/lcg, 0.001
mg/kg, 0.005 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1.0 mg/kg,
1.5 mg/kg,
-41 -



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
or 2 mg/kg of patient body weight. In related embodiments the effective amount
of
norepinephrine is about 0.0001 mg/kg to 0.001 mg/kg, 0.01 mg/kg to 0.1 mg/kg,
or 1.0 mg/kg
to 2 mg/kg of patient body weight. In related embodiments the effective amount
of
norepinephrine is about 0.0005 mg/kg to 0.005 mg/kg, 0.05 mg/kg to 0.5 mg/kg,
or 1.5 mg/kg
to 2 mg/kg of patient body weight.
In one embodiment, the composition topically administered to a patient in the
methods of the invention comprises an effective amount of the vasoconstrictor
SerotoninTM in
a concentration in the range of about 0.0001 mg/kg of patient body weight to
about 750
mg/kg of patient body weight. For adults the preferred SerotoninTM
concentration range is
about 0.001 mg/kg to about 0.6 mg/kg. In related embodiments the effective
amount of
SerotoninTM is approximately 0.001 mg/kg, 0.005 mg/kg, 0.01 mg/kg, 0.05 mglkg,
0.1 mglkg,
0.5 mg/kg, 1.0 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg, 60
mg/kg, 70
mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 110 mg/kg, 120 mg/kg, 130 mg/kg, 140
mg/kg, 150
mg/kg, 160 mg/kg, 170 mg/kg, 180 mg/kg, 190 mg/kg, 200 mg/kg, 210 mg/kg, 250
mg/kg,
300 mg/kg, 350 mg/kg, 400 mg/kg, 450 mg/kg, 500 mglkg, 550 mg/kg, 600 mg/kg,
650
mg/kg, 700 mg/kg, or 750 mg/kg of patient body weight. In related embodiments
the
effective amount of SerotoninTM is about 0.001 mg/kg to 0.01 mg/kg, 0.1 mg/kg
to 1.0 mg/kg,
mg/kg to 40 mg/kg, 60 mg/kg to 80 mg/kg, 100 mg/kg to 120 mg/kg, 140 mg/kg to
160
mg/kg, 180 mg/kg to 200 mg/kg, 210 mg/kg to 300 mg/kg, 400 mg/kg to 500 mg/kg,
or 600
20 mg/kg to 700 mg/kg of patient body weight. In related embodiments the
effective amount of
SerotoninTM is about 0.005 mg/kg to 0.05 mg/lcg, 0.5 mg/kg to 10 mg/kg, 30
mg/kg to 50
mg/kg, 70 mg/kg to 90 mg/kg, 110 mg/kg to 130 mg/kg, 150 mg/kg to 170 mg/kg,
190 mg/kg
to 210 mg/lcg, 250 mg/kg to 350 mg/kg, 450 mg/kg to 550 mg/kg,~or 650 mg/lcg
to 750 mglkg
of patient body weight.
In one embodiment, the composition topically administered to a patient in the
methods of the invention comprises an effective amount of the vasoconstrictor
endothelin in a
concentration in the range of about 4.5x10'8 mg/kg of patient body weight to
about 5.0x10'6
mg/kg of patient body weight. In related embodiments the effective amount of
endothelin is
approximately 4.5x 10-$ mg/kg, 5.0x 10-8 mg/kg, 5.5x 10-8 mg/kg, 6.Ox 10-8
mg/kg, 6.5x 10-8
mg/kg, 7.Ox10-g mg/kg, 7.5x10-8 mglkg, 8.0x10-$ mg/kg, 8.5x10-8 mg/kg, 9.0x10-
$ mg/kg,
9. Sx 10-8 mg/kg, 1.Ox 10-7 mg/kg, 1. Sx 10-7 mg/kg, 2.Ox 10-7 mg/kg, 2. Sx 10-
7 mg/kg, 3 .Ox 10-7
mg/kg, 3. Sx 10-7 mg/kg, 4.Ox 10-7 mg/kg, 4. Sx 10-7 mg/kg, S .Ox 10-7 mg/kg,
S. Sx 10-7 mg/kg,
-42-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
6.Ox 10-7 mg/kg, 6.5x 10-7 mg/kg, 7.Ox 10-7 mg/kg, 7.5x 10-7 mg/kg, 8.Ox 10-7
mg/kg, 8.5x 10-7
mg/kg, 9.Ox 10-7 mg/kg, 1.Ox 10-6 mg/kg, 1.5x 10-6 mg/kg, 2.Ox 10-6 mg/kg,
2.5x 10-6 mg/kg,
3.0x10-6 mg/kg, 3.5x10-6 mglkg, 4.0x10-6 mg/kg, 4.5x10-6 mg/kg, or 5.0x10-6
mg/kg of patient
body weight. In related embodiments the effective amount of endothelin is
about 5.0x10-8
mg/kg to 6.Ox 10-$ mg/kg, 7.Ox 10-8 mg/kg to B.Ox 10-s mg/kg, 9.Ox 10-8 mg/kg
to 1.Ox 10-7
mg/kg, 2.Ox 10-7 mg/kg to 3.Ox 10-7 mg/kg, 4.Ox 10-7 mg/kg to S.Ox 10-7 mg/kg,
6.Ox 10-7 mg/kg
to 7.Ox 10-7 mg/kg, 8.Ox 10-7 mg/kg to 9.Ox 10-7 mg/kg, 1.Ox 10-6 mg/kg to
2.Ox 10-6 mg/kg,
3.0x10-6 mg/kg to 4.0x10-6 mg/kg, or 4.0x10-6 mg/kg to 5.0x10-6 mg/kg of
patient body
weight. In related embodiments the effective amount of endothelin is about
4.5x10-8 mg/kg
to 5.5x10-$ mg/kg, 6.5x10-8 mglkg to 7.5x10-8 mg/lcg, 8.5x10-8 mg/kg to 9.5x10-
8 mg/kg,
1.5x10-7 mg/kg to 2.5x10-7 mg/kg, 3.5x10-7 mg/kg to 4.5x10-7 mg/kg, 5.5x10-7
mg/kg to
6.5x10-7mg/kg, 7.5x10-7mg/kg to 8.5x10-7mg/kg, 1.5x10-6mg/kg to 2.5x10-6mg/kg,
or
3.5x10-6 mg/kg to 4.5x10-6 mg/kg of patient body weight.
For other vasoconstrictors, including but not limited to, endothelin-1,
epinephrine, phenylephrine, thromboxane, prostaglandin, methergine, oxytocin,
isopreland
U-46619, papaverine, yohimbine, visnadin, khellin, bebellin, and nicotinate
derivatives, one
skilled in the art would be able to determine appropriate effective doses
using the methods
described in sections 5.2 and 5.4. In related embodiments the effective amount
of a
vasoconstrictor is approximately 4.5x10-8 mg/kg, 5.0x10-8 mglkg, 6.0x10-8
mglkg, 7.0x10-8
mg/kg, 8.Ox 10-8 mg/kg, 9.Ox 10-8 mg/kg, , 1.Ox 10-7 mg/kg, 2.Ox 10-7 mg/kg,
3.Ox 10-7 mg/kg,
4.Ox 10-7 mg/kg, S.Ox 10-7 mg/kg, 6.Ox 10-7 mg/kg, 7.Ox 10-7 mg/kg, B.Ox 10-7
mglkg, 9.Ox 10-7
mg/kg, 1.Ox 10-6 mg/kg, 2.Ox 10-6 mg/kg, 3.Ox 10-6 mg/kg, 4.Ox 10-6 mg/kg,
S.Ox 10-6 mg/kg,
6.Ox 10-6 mg/lcg, 7.Ox 10-6 mg/kg, 8.Ox 10-6 mg/kg, 9.Ox 10-6 mg/kg, 1.Ox 10-5
mg/kg, 2.Ox 10-5
mg/kg, 3.Ox 10-5 mg/kg, 4.Ox 10-5 mg/kg, S.Ox 10'5 mg/kg, 6.Ox 10-5 mg/kg,
7.Ox 10-5 mg/kg,
8.Ox 10-5 mg/kg, 9.Ox 10-5 mg/kg, 1.Ox 10-4 mg/kg, 2.Ox 10-4 mg/kg, 3.Ox 10-4
mg/kg, 4.Ox 10-4
mg/kg, S.Ox 10-4 mg/kg, 6.Ox 10-4 mg/kg, 7.Ox 10-4 mg/lcg, 8.Ox 10-4 mg/kg,
9.Ox 10-4 mg/kg,
1.Ox 10-3 mg/kg, 2.Ox 10-3 mg/kg, 3.Ox 10-3 mg/kg, 4.Ox 10-3 mg/kg, S.Ox 10-3
mg/kg, 6.Ox 10-3
mg/kg, 7.Ox 10-3 mg/kg, B.Ox 10-3 mg/kg, 9.Ox 10-3 mg/kg, 1.Ox 10-2 mg/kg,
2.Ox 10-2 mg/kg,
3.Ox 10-2 mg/kg, 4.Ox 10-2 mg/kg, S.Ox 10-2 mg/lcg, 6.Ox 10-2 mg/kg, 7.Ox 10-2
mg/kg, 8.Ox 10-2
mg/kg, 9.0x10-2 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 10 mg/kg, 20 mg/kg, 30
mg/kg, 40
mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 110 mg/kg,
120
mg/kg, 130 mg/kg, 140 mg/kg, 150 mg/kg, 160 mg/kg, 170 mg/kg, 180 mg/kg, 190
mg/kg,
-43-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
200 mg/kg, 210 mg/kg, 250 mg/kg, 300 mg/kg, 350 mg/kg, 400 mglkg, 450 mg/kg,
500
mg/kg, 550 mg/kg, 600 mg/kg, 650 mg/kg, 700 mg/kg, 750 mg/kg, 800 mg/kg, 850
mg/kg,
900 mg/kg, 950 mg/kg, 1000 mg/kg, 1100 mg/kg, 1200 mg/kg, 1300 mg/kg, 1400
mg/kg, or
1500 mg/kg of patient body weight.
S In certain embodiments, the effective amount of a vasoconstrictor is in the
range of about 6.Ox 10'8 mg/kg to 1.Ox 10'7 mg/kg, 1.Ox 10-~ mg/kg to 4.Ox
10'7 mg/kg, 4.Ox 10'7
mg/kg to 8.Ox 10'7 mg/kg, 8.Ox 10'7 mg/kg to 2.Ox 10'6 mg/kg, 2.Ox 10'6 mg/kg
to 6.Ox 10'6
mg/kg, 6.Ox 10'6 mglkg to 1.Ox 10'5 mg/kg, l .Ox 10'5 mg/kg to 4.Ox 10'5
mg/kg, 4.Ox 10'5 mg/kg
to 8.Ox 10'5 mg/kg, 8.Ox 10'5 mg/kg to 2.Ox 10-4 mg/kg, 2.Ox 10-~ mglkg to
6.Ox 10'4 mg/kg,
6.Ox 10'4 mg/kg to 1.Ox 10'3 mg/kg, l .Ox 10'3 mg/kg to 4.Ox 10'3 mg/kg, 4.Ox
10'3 mg/kg to
8.Ox 10-3 mg/kg, 8.Ox 10'3 mg/kg to 2.Ox 10'2 mg/kg, 2.Ox 10'2 mg/kg to 6.Ox
10'2 mg/kg, 6.Ox 10'2
mg/kg to 0.1 mg/kg, 0.1 mg/kg to 0.4 mg/kg, 0.4 mg/kg to 0.8 mg/kg, 0.8 mg/kg
to 2.0
mg/kg, 2.0 mg/kg to 6.0 mg/kg, 6.0 mg/kg to 10 mg/kg, 10 mg/kg to 40 mg/kg, 40
mg/kg to
80 mg/kg, 80 mg/kg to 120 mg/kg, 120 mg/kg to 160 mg/kg, 160 mg/kg to 200
mg/kg, 200
mg/kg to 240 mg/kg, 280 mg/kg to 320 mg/kg, 320 mg/kg to 360 mg/kg, 360 mg/kg
to 400
mglkg, 400 mg/kg to 440 mg/kg, 440 mg/kg to 480 mglkg, 480 mg/kg to 520 mg/kg,
520
mg/lcg to 560 mg/kg, 560 mg/kg to 600 mg/kg, 600 mg/kg to 640 mg/kg, 640 mg/kg
to 680
mg/kg, 680 mg/kg to 720 mg/kg, 720 mg/kg to 760 mg/kg, 760 mg/kg to 800 mg/kg,
800
mg/kg to 840 mg/kg, 840 mg/kg to 880 mg/kg, 880 mg/kg to 920 mg/kg, 920 mg/kg
to 960
mg/kg, 960 mg/kg to 1000 mg/kg, 1000 mg/kg to 1040 mg/kg, 1040 mg/kg to 1080
mg/kg,
1080 mg/kg to 1120 mg/kg, 1120 mg/kg to 1160 mg/kg, 1160 mg/kg to 1200 mg/kg,
1200
mglkg to 1240 mg/kg, 1240 mg/kg to 1280 mg/kg, 1280 mg/kg to 1320 mg/kg, 1320
mg/kg
to 1360 mg/kg, 1360 mg/lcg to 1400 mg/kg, 1400 mg/kg to 1440 mg/kg, 1440 mg/kg
to 1480
mg/kg, or 1480 mg/lcg to 1520 mg/kg of patient body weight.
In certain embodiments, the effective amount of a vasoconstrictor is in the
range of about 4. Sx 10'g mg/kg to 8.Ox 10'8 mg/kg, 8.Ox 10'8 mg/kg to 2.Ox 10-
7 mg/kg, 2.Ox 10'7
mg/kg to 6.Ox 10'7 mg/kg, 6.Ox 10'7 mg/kg to l .Ox 10'6 mg/kg, 1.Ox 10'6 mg/kg
to 4.Ox 10'6
mg/lcg, 4.Ox 10'6 mg/kg to 8.Ox 10'6 mg/kg, B.Ox 10'6 mg/kg to 2.Ox 10'5
mg/kg, 2.Ox 10'5 mg/kg
to 6.Ox 10'5 mg/kg, 6.Ox 10'5 mg/kg to 1.Ox 10'4 mg/kg, 1.Ox 10'4 mg/kg to
4.Ox 10'4 mg/lcg,
3 0 4.Ox 10'4 mg/lcg to B.Ox 10'4 mg/kg, 8.Ox 10'4 mg/kg to 2.Ox 10'3 mg/kg,
2. Ox 10'3 mg/kg to
6.Ox 10'3 mg/kg, 6.Ox 10-3 mg/kg to 1.Ox 10'2 mg/kg, l .Ox 10'2 mg/kg to 4.Ox
10'2 mg/kg, 4.Ox 10'2
mg/kg to 8.Ox 10'2 mg/kg, 8.Ox 10'2 mg/kg to 0.2 mg/kg, 0.2 mg/kg to 0.6
mg/kg, 0.6 mg/kg to
-44-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
1.0 mg/kg, 1.0 mg/kg to 4.0 mg/kg, 4.0 mg/kg to 8.0 mg/kg, 8.0 mg/kg to 12
mg/kg, 12
mg/kg to 16 mg/kg, 16 mg/kg to 20 mg/kg, 20 mg/kg to 60 mg/kg, 60 mg/kg to 100
mg/kg,
100 mg/kg to 140 mg/kg, 140 mg/kg to 180 mg/lcg, 180 mg/kg to 220 mg/kg, 220
mg/kg to
260 mg/kg, 260 mg/kg to 300 mg/kg, 300 mg/kg to 340 mg/kg, 340 mg/kg to 380
mg/lcg, 380
mg/kg to 420 mg/kg, 420 mg/kg to 460 mg/kg, 460 mg/kg to 500 mg/kg, 500 mg/kg
to 540
mg/kg, 540 mg/kg to 580 mg/kg, 580 mg/kg to 620 mg/kg, 620 mg/kg to 660 mg/kg,
660
mglkg to 700 mg/kg, 700 mg/kg to 740 mg/lcg, 740 mg/kg to 780 mg/kg, 780 mg/kg
to 820
mg/kg, 820 mg/kg to 860 mg/kg, 860 mg/kg to 900 mg/kg, 900 mg/kg to 940 mg/kg,
940
mg/kg to 980 mg/lcg, 980 mg/kg to 1020 mg/kg, 1020 mglkg to 1060 mg/kg, 1060
mg/kg to
1100 mg/kg, 1100 mglkg to 1140 mg/kg, 1140 mg/kg to 1180 mg/kg, 1180 mg/kg to
1220
mg/kg, 1220 mg/kg to 1260 mg/kg, 1260 mg/kg to 1300 mg/kg, 1300 mg/kg to 1340
mg/kg,
1340 mg/kg to 1380 mg/kg, 1380 mg/kg to 1420 mg/kg, 1420 mg/kg to 1460 mg/kg,
or 1460
mg/kg to 1500 mg/kg of patient body weight.
In general, the effective does of a vasoconstrictor used in the compositions
of
the methods, compositions, and kits of the invention is a concentration that
is less than an
amount that would cause systemic vasoconstriction when administered
intravenously and
greater than an amount that would have only a localized effect when applied to
the skin
surface rather than effecting a breach or puncture in a vein or artery.
The effective amount of a vasoconstrictor can also be described in the context
of particular formulations of the compositions used in the methods,
compositions, and kits of
the invention. For example, where the composition is formulated as or applied
to a patch for
administration following a cardiac catheterization procedure, adrenaline is
the vasoconstrictor
used in the composition, and the patient is an adult weighing about 70 kg,
then the patch
should comprise adrenaline in the concentration range of about 0.00075 mg/kg
to about 37.5
mg/lcg. Since a patch used in such procedures is typically about 4 cm2 to 25
cmz, depending
on the F size of the catheter used, one skilled in the art could readily
determine the
concentration in units of mg of adrenaline per cm2 of patch, e.g., about
0.00020 mg/cm2 to
about 1.5 mg/cm2. Similarly, for example, where the composition is formulated
as a gel or
liquid, for administration following a cardiac catheterization procedure,
adrenaline is the
vasoconstrictor used in the composition, and the patient is an adult weighing
about 70 kg,
then the gel should comprise adrenaline in the concentration range of about
0.00075 mg/kg to
about 37.5 mg/kg. Since a gel used in such procedures is typically about 1-2
ml, one skilled
- 45 -



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
in the art could readily determine the concentration in units of mg of
adrenaline per ml of gel,
e.g., about 0.00075 mg/ml to about 18.75 mg/ml.
The example conversion calculation described above can be performed to
allow the extrapolation of suitable concentration ranges for topical
application any of the
dosage ranges for any of the vasoconstrictors and/or coagulants described
herein above or
any vasoconstrictors andlor coagulant suitable for use in the methods,
compositions, and kits
of the invention. In preferred embodiments, where the composition is
formulated as a patch,
gel, or liquid, such compositions can be manufactured for general use for
adults, e.g., adults
weighing about 50, 60, 70, 80, or 90 kg, and a topical administration area,
e.g., of a patch, of
about 1-2, 2-4, 4-8, 8-12, 12-15, 15-20, 20-25, or 25-30 cmz, or a topical
administration
volume, e.g., of a liquid or gel, of about 0.25-0.5, 0.5-1, 1-1.25, 1.25-1.5,
1.5-1.75, 1.75-2, 2-
2.5, or 2.5-3 ml.
5.5 KITS
A kit is also provided which according to the invention comprises any of the
above described embodiments. The kit can include the composition contained
within a
sealed, water proof, sterile package which facilitates removal of the
composition without
contamination. Materials from which containers may be made include aluminum
foil, plastic,
or another conventional material that is easily sterilized. The kit can
contain a single
composition or multiple compositions, preferably wherein each is provided in a
separate,
waterproof, sterile package.
In another embodiment, a container having dual compartments is provided. A
first compartment contains the composition, while the second compartment
contains a topical
barrier, membrane, or film according to the invention. In field use, the
barrier, membrane, or
film can be readily dipped into an opened first compartment ans subsequently
applied to the
wound. The composition can be applied or added to a topical barrier, membrane,
or film
prior to being packaged and sterilized or the composition can be formulated as
a barrier,
membrane, or film. In another embodiment, the kit may not contain a barrier,
membrane, or
film if the composition is not formulated as such.
According to one aspect of the invention, various specialized kits can be
provided. The kit can contain multiple compositions of the invention, wherein
each is
-46-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
contained within a separate sealed sterile package or container. The kit can
contain in one or
more containers, a an effective amount of a vasoconstrictor, wherein the
vasoconstrictor does
not comprise a poly-~i-1-j 4 N-acetylglucosamine polymer or derivative
thereof, while in
another separate container a pharmaceutically acceptable carrier can be
packaged. In a
separate container the kit can contain a neutral liquid, neutral gel or
neutral solid. The kit
may also contain a coagulant in accord with the composition of the invention
as described
herein.
The kit can comprise a composition that can be formulated as a barrier-
forming material that forms a barner to blood. The kit can comprise a
composition that can
coat, be added to, or integrated into a barrier-forming material that forms a
barner to blood.
In one embodiment a kit comprises a pharmaceutical composition comprising a
patch made
of barrier-forming materials that are embedded with one or more coagulant
and/or
vasoconstrictor agent(s). In one embodiment a kit comprises a pharmaceutical
composition
comprising a gauze embedded with one or more coagulant and/or vasoconstrictor
agent(s).
In certain embodiments, a kit comprises pharmaceutical compositions comprising
a barrier-
forming material embedded or combined with one or more coagulant and/or
vasoconstrictor
agent(s), wherein the barrier-forming material contains an adhesive so that
the material can
be adhere to a patient's skin surface. Alternatively, a kit lacks barrier-
forming materials.
A kit can comprise a notice regarding FDA approval and/or instructions for
use at a distance and/or in combination with compression.
A kit may be prescribed, for example, to patients requiring anticoagulant
therapy, to avert the risk of serious bleeding which can occur from minor
injury. A kit may
be used, for example, to treat a breach or puncture in a vein or artery
resulting from
catheterization. In one embodiment a kit comprises a patch embedded or coated
with a
vasoconstrictor, a coagulant, or an agent that functions as both a
vasoconstrictor or coagulant.
In another embodiment a kit comprises a gel that can be used in the methods of
the invention,
wherein the gel comprises a vasoconstrictor, a coagulant, or an agent that
functions as both a
vasoconstrictor or coagulant.
Additionally, a kit designed for emergency or military use can also contain
disposable pre-sterilized instruments, such as scissors, scalpel, clamp,
tourniquet, elastic or
inelastic bandages, or the like. In a preferred embodiment the kit contains
gauze.
-47-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
6. EXAMPLE 1: DETERMINING RATE OF CESSATION OR TIME TO
ACHIEVE CESSATION OF BLOOD FLOW
This blinded, randomized, placebo controlled trial is designed to examine an
arterial puncture of a femoral artery in dogs intended to simulate cardiac
catheterization.
This method takes into consideration differences in bleeding time and the
amount of
compression applied.
6.1 MATERIALS AND METHODS
Dogs are randomly assigned to have either compression in conjunction with a
topical barrier-forming material without a vasoconstrictor or coagulant or a
barrier-forming
material coated with or formulated from the composition of the invention in
conjunction with
compression.
In preferred embodiments, the animal model provides a control. For example,
in dogs the femoral arteries in each hind leg can be punctured in an identical
manner to create
comparable punctures and the treatment being tested can be applied to one
puncture while the
other is left untreated or receives compression alone.
A mechanical pressure clamp is applied over the barrier-forming material. At
5 minute intervals, the clamp is loosened to check for blood flow from the
wound site, but the
barrier-forming material is not disturbed. If blood continues to flow from the
wound, the
clamp is re-applied until bleeding completely stops, with checks performed
every five
minutes. A fluid-filled balloon connected to a pressure transducer is used to
measure the
amount of pressure applied. A pre-procedure bleeding time is also preformed.
By comparing pre-procedure bleeding variables such as pre-procedure
hematocrit (%) and bleeding time (mins), for each group differences in
bleeding can be
eliminated through selection of particular animals, or compensated for by
calculating the rate
of cessation or time to achieve cessation of bleeding from a base values.
Clamp pressure applied to the femoral arterial puncture site can be carefully
controlled and recorded for each dog, allowing calculation of a mean clamp
pressure (rnmHg)
for both the placebo group and the group receiving the composition of the
invention.
The superficial nature of the femoral artery in dogs allows for direct and
consistent visualization of hematoma formation. Visualization can be by any of
the methods
-48-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
described herein such as ultrasonography, or scintigraphic imaging. External
signs are also
indicative of hematoma formation, including ecchymosis (blue or purplish skin
discoloration
greater than or equal to 2.5 cm in diameter), swelling (greater than or equal
to 2.5 cm in
diameter and 0.5 cm in height). The carmula can also be removed from the dogs
following
application of the methods of the invention to determine frequency of
hematomas or other
vascular complications.
Percent differences between mean values for each treatment group are
calculated for several variables including, pre-procedure hematocrit (%), pre-
procedure
bleeding time (mins), time to cessation of bleeding from the puncture site
(mins), the mean
numbers of hematomas, and mean clamp pressure (mmHg). The statistical
significance (P
values) of the differences between the mean values for each variable are
calculated by
standard statistical methods.
The present invention is not to be limited in scope by the specific
embodiments described herein. W deed, various modifications of the invention
in addition to
those described will become apparent to those skilled in the art from the
foregoing
description and accompanying figures. Such modifications are intended to fall
within the
scope of the appended claims.
Various publications are cited herein, the disclosures of which are
incorporated by reference in their entireties.
The present invention is not to be limited in scope by the specific
embodiments described herein. Indeed, various modifications of the invention
in addition to
those described will become apparent to those skilled in the art from the
foregoing
description and accompanying figures. Such modifications are intended to fall
within the
scope of the appended claims.
Various publications are cited herein, the disclosures of which are
incorporated by reference in their entireties.
The invention can be illustrated by the following embodiments enumerated in
the numbered paragraphs that follow:
1. A method for treating a breach or puncture in a vein or artery of a
patient, comprising:
-49-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
a) applying topically to the patient's skin over a wound contiguous with the
breach or puncture in the vein or artery a composition comprising an effective
amount of a vasoconstrictor, wherein the vasoconstrictor does not comprise a
poly-(3-1-j 4 N-acetylglucosamine polymer or derivative thereof; and
concurrently
b) applying compression to the breached or punctured vein or artery,
wherein a cessation or reduction of blood flow out of the breach or puncture
in the
vein or artery is achieved at a greater rate or in less time than applying
compression in
conjunction with a topical barrier-forming material without the
vasoconstrictor.
2. A method for achieving a cessation of blood flow or sealing of a
breach or puncture in a vein or artery and a cessation of blood flow or
sealing of a skin
surface wound that is contiguous with the breach or puncture comprising:
a) applying topically to the patient's skin over a wound contiguous with a
breach
or puncture in a vein or artery a composition comprising a vasoconstrictor or
coagulant, wherein the vasoconstrictor or coagulant does not comprise a
poly-~i-1-~ 4 N-acetylglucosamine polymer or derivative thereof;
b) concurrently applying compression to the breached or punctured vein or
artery; and
c) recording the amount of blood flow from the wound and the puncture,
wherein an amount of the vasoconstrictor or coagulant is effective to increase
sealing
or decrease cessation of blood flow from the breach or puncture in the vein or
artery and
increase sealing or decrease cessation ofblood flow from the skin surface
wound, in
comparison to applying compression in conjunction with a topical barner-
forming material
without the vasoconstrictor.
3. A method for treating a breach or puncture in a vein or artery of a
patient, comprising:
a) applying topically to the patient's skin over a wound contiguous with the
breach or puncture in the vein or artery a composition comprising an effective
amount of a
coagulant, wherein the coagulant does not comprise a poly-~3-1-~ 4 N-
acetylglucosamine
polymer or derivative thereof; and concurrently
b) applying compression to the breached or punctured vein or artery,
-50-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
wherein a cessation or reduction of blood flow out of the breach or puncture
in the
vein or artery is achieved at a greater rate in less time than applying
compression in
conjunction with a topical barrier-forming material without a coagulant.
4. A method for treating a breach or puncture in a vein or artery of
a patient, comprising:
a) applying topically to the patient's skin over a wound contiguous with the
breach or puncture in the vein or artery a composition comprising an effective
amount of a vasoconstrictor and a coagulant, wherein the vasoconstrictor and
the coagulant do not comprise a poly-(3-1-j 4 N-acetylglucosamine polymer or
derivative thereof; and concurrently
b) applying compression to the breached or punctured vein or artery,
wherein a cessation or reduction of blood flow out of the breach or puncture
in the
vein or artery is achieved at a greater rate or in less time than applying
compression in
conjunction with a topical barner-forming material without the vasoconstrictor
and the
coagulant.
5. The method of any one of paragraphs 1-4, wherein the composition
further comprises an anti-fungal or antibacterial agent.
6. The method of any one of paragraphs 1-4, wherein the composition
further comprises collagen.
7. The method of any one of paragraphs 1-4, wherein the composition
further comprises a pharmaceutical Garner.
8. The method of any one of paragraphs 1-4, wherein the composition is
formulated as a gel, solid, liquid, sponge, foam, spray, emulsion, suspension,
or solution.
9. The method of any one of paragraphs 1-4, wherein the composition
further comprises a neutral liquid, neutral gel or neutral solid.
10. The method of paragraph 9, wherein the composition further comprises
a neutral solid and wherein the neutral solid is a gauze.
11. The method of paragraph 8, wherein the composition is in the form of
a coating on a neutral solid.
12. The method of paragraph 11, wherein the neutral solid is a gauze.
13. The method of any one of paragraphs 1-4, wherein the barner-forming
material is a gauze.
-51-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
14. The method of any one of paragraphs 2, 3, or 4, wherein the coagulant
is selected from the group consisting of alpha-2-antiplasmin, alpha-1-
antitrypsin, alpha-2-
macroglobulin, aminohexanoic acid, aprotinin, a source of Calcium ions,
calcium alginate,
calcium-sodium alginate, casein Kinase II, clutin, chitosan, collagen,
cyanoacrylates,
epsilon-aminocaproic acid, Factor XIII, fibrin, fibrin glue, fibrinogen,
fibronectin, gelatin,
living platelets, metha crylates, PAI-1, PAI-2, plasmin activator inhibitor,
plasminogen,
platelet agonists, protamine sulfate, prothrombin, an RGD peptide,
sphingosine, a
sphingosine derivative, thrombin, thromboplastin, and tranexamic acid.
15. The method of any one of paragraphs 1 or 4, wherein the
vasoconstictor is selected from the group consisting of adrenaline, endothelin-
1, epinephrine,
phenylephrine, serotonin, thromboxane, and U-46619.
16. The method of any one of paragraphs 1-4, wherein the patient is a
human.
17. The method of any one of paragraphs 1-4, wherein composition
applied is a film or membrane.
18. The method of paragraph 17, wherein the film or membrane comprises
a barrier-forming material.
19. The method of any one of paragraphs 1-4, wherein composition is
formulated as a mat, string, microbead, microsphere, or microfibril.
20. The method of any one of paragraphs 1-4, wherein the composition
further comprises a biodegradable material.
21. The method of paragraph 20, wherein the biodegradable material is
selected from the group consisting of a polyanionic polysaccharide, alginic
acid, collagen, a
polypeptide, a polyglycolide, a polylactide, a polycaprolactone, dextran and a
copolymer of
dextran, a polyglycolide, a polylactide, a polydioxanone, a
polyestercarbonate, a
polyhydroxyalkonate, and a polycaprolactone and a copolymer thereof.
22. The method of any one of paragraphs 1-4, further comprising before
step (a) the step of administering to the patient an anticoagulant.
23. The method of paragraph 22, wherein the anticoagulant is selected
from the group consisting of coumadin, heparin, nadroparin, asparin, and a
thrombolytic
agent.
-52-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
24. The method of paragraph 23, wherein the composition further
comprises protamine sulfate in an amount effective to neutralize heparin.
25. The method of any one of paragraphs 1-4, wherein the artery is the
femoral, radial, brachial, or axillary artery.
26. The method of any one of paragraphs 1-4, wherein the vein is the
femoral, internal jugular, or subclavian vein. .
27. The method of any one of paragraphs 1-4, wherein the compression is
manual compression.
28. The method of any one of paragraphs 1-4, wherein the compression is
mechanical compression.
29. The method of any one of paragraphs 1-4, wherein the compression is
applied to the vein or artery proximal of the puncture or breach.
30. The method of any one of paragraphs 1-4, wherein the compression is
applied at the site of application of the composition.
31. The method of any one of paragraphs 1-4, wherein the compression is
applied with a compression bandage.
32. The method of any one of paragraphs 1-4, further comprising,
repeating step (b).
33. The method of paragraph 32, wherein the rate is at least 10% greater
than applying compression in conjunction with a topical barrier-forming
material without a
vasoconstrictor.
34. The method of paragraph 32, wherein the rate is at least 20% greater
than applying compression in conjunction with a topical barrier-forming
material without a
vasoconstrictor.
35. The method of paragraph 32, wherein the rate is at least 30% greater
than applying compression in conjunction with a topical barrier-forming
material without a
vasoconstrictor.
36. The method of paragraph 32, wherein the rate is at least 40% greater
than applying compression in conjunction with a topical barrier-forming
material without a
vasoconstrictor.
-53-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
37. The method of paragraph 32, wherein the rate is at least 50% greater
than applying compression in conjunction with a topical barner-forming
material without a
vasoconstrictor.
38. The method of any one of paragraphs 1-4, wherein the vein or artery is
breached or punctured by a catheter.
39. The method of any one of paragraphs 1-4, wherein the skin wound
contiguous with the breach or puncture in the vein or artery is 10, 9, 8, 7,
6, 5, or 4 cm from
the puncture in the vein or artery.
40. A method for decreasing the occurrence of localized vascular
complications comprising:
a) applying topically to the patient's skin over a wound contiguous with a
breach
or puncture in a vein or artery a composition comprising a vasoconstrictor or
coagulant, wherein the vasoconstrictor or coagulant does not comprise a
poly-,Q-1-3 4 N-acetylglucosamine polymer or derivative thereof;
b) concurrently applying compression to the breached or punctured vein or
artery; and
c) recording the occurrence of localized vascular complications,
wherein an amount of the vasoconstrictor or coagulant is effective to cause
sealing of
the breach or puncture in the vein or artery, reducing the rate of localized
vascular
complications in comparison to applying compression in conjunction with a
topical barrier-
forming material without a vasoconstrictor.
41. The method of paragraph 40, wherein the rate is 50% less than
applying compression in conjunction with a topical barrier without a
vasoconstrictor.
42. The method of paragraph 40, wherein the vein or artery is breached or
punctured by a catheter.
43. A pharmaceutical composition for topically treating a breach or
puncture in a vein or artery, comprising:
a) an effective amount of a vasoconstrictor, wherein the vasoconstrictor does
not
comprise a poly-~3-1-j 4 N-acetylglucosamine polymer or derivative thereof;
and
b) a pharmaceutically acceptable carrier.
-54-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
44. The pharmaceutical composition of paragraph 43, wherein the
composition further comprises a coagulant.
45. The pharmaceutical composition of paragraphs 43 or 44, further
comprising a neutral liquid, neutral gel or neutral solid.
46. The pharmaceutical composition of paragraph 45, wherein the
composition further comprises a neutral solid and wherein the neutral solid is
a gauze.
47. A kit comprising in one or more containers a composition comprising:
a) an effective amount of a vasoconstrictor, wherein the vasoconstrictor does
not
comprise a poly-,Q-1-j 4 N-acetylglucosamine polymer or derivative thereof;
and
b) a pharmaceutically acceptable carrier,
and instructions for topically treating a breach or puncture in a vein or
artery.
4~. The kit of paragraph 47, wherein the composition further comprises a
coagulant.
49. The kit of paragraph 47, further comprising a neutral liquid, neutral
gel or neutral solid.
50. The kit of paragraph 49, wherein the composition further comprises a
neutral solid and wherein the neutral solid is a gauze.
51. The kit of paragraph 49, wherein the composition further comprises a
neutral gel and wherein the neutral gel is gelatin.
52. A pharmaceutical composition for topically treating a breach or
puncture in a vein or artery, comprising:
a) an effective amount of a vasoconstrictor, wherein the vasoconstrictor does
not
comprise a poly-(3-1-j 4 N-acetylglucosamine polymer or derivative thereof;
and
b) wherein the vasoconstrictor is formulated into a barner, membrane, or film.
53. The pharmaceutical composition of paragraph 52, wherein the
composition further comprises a coagulant.
54. The pharmaceutical composition of paragraphs 52 or 53, further
comprising a neutral liquid, neutral gel or neutral solid.
55. The pharmaceutical composition of paragraph 52, wherein the
composition further comprises a neutral solid and wherein the neutral solid is
a gauze.
56. A kit comprising in one or more containers a composition comprising:
-55-



CA 02511807 2005-06-27
WO 2004/060172 PCT/US2003/041762
a) an effective amount of a vasoconstrictor, wherein the vasoconstrictor
does not comprise a poly-,Q-1-j 4 N-acetylglucosamine polymer or
derivative thereof; and
b) wherein the vasoconstrictor is formulated into a barrier, membrane, or
film,
and instructions for topically treating a breach or puncture in a vein or
artery.
57. The kit of paragraph 56, wherein the composition further comprises a
coagulant.
58. The kit of paragraph 56, wherein the composition further comprises a
neutral liquid, neutral gel or neutral solid.
59. The kit of paragraph 56, wherein the composition further comprises a
neutral solid and wherein the neutral solid is a gauze.
60. The kit of paragraph 56, wherein the vasoconstrictor is AdrenalineTM
and the composition comprises about 0.00001 mg/kg to about 0.5 mg/kg of
patient body
weight of AdrenalineTM
61. The kit of paragraph 56, wherein the vasoconstrictor is metaraminol
bitartrate and the composition comprises about 0.0005 mg/kg to about 4.5 mg/kg
of patient
body weight of metaraminol bitartrate.
62. The kit of paragraph 56, wherein the vasoconstrictor is dopamine HCl
and the composition comprises about 0.0005 mg/kg to about 10 mg/kg of patient
body weight
of dopamine HCI.
63. The lcit of paragraph 56, wherein the vasoconstrictor is isoproterenol
HCl and the composition comprises about 0.0005 mg/kg to about 5 mg/kg of
patient body
weight of isoproterenol HCI.
64. The kit of paragraph 56, wherein the vasoconstrictor is norepinephrine
and the composition comprises about 0.0001 mglkg to about 0.01 mg/kg of
norepinephrine.
65. The kit of paragraph 56, wherein the vasoconstrictor is SerotoninTM
and the composition comprises about 0.001 mg/kg to about 0.6 mg/kg of patient
body weight
of SerotoninTM
66. The kit of paragraph 56, wherein the vasoconstrictor is endothelin and
the composition comprises about 4.5x10-8 mg/kg to about S.OxlO-6 mg/kg of
patient body
weight of endothelin.
-56-

Representative Drawing
A single figure which represents the drawing illustrating the invention.
Administrative Status

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Administrative Status , Maintenance Fee  and Payment History  should be consulted.

Administrative Status

Title Date
Forecasted Issue Date Unavailable
(86) PCT Filing Date 2003-12-31
(87) PCT Publication Date 2004-07-22
(85) National Entry 2005-06-27
Examination Requested 2008-12-22
Dead Application 2012-10-11

Abandonment History

Abandonment Date Reason Reinstatement Date
2011-10-11 R30(2) - Failure to Respond
2012-01-03 FAILURE TO PAY APPLICATION MAINTENANCE FEE

Payment History

Fee Type Anniversary Year Due Date Amount Paid Paid Date
Registration of a document - section 124 $100.00 2005-06-27
Application Fee $400.00 2005-06-27
Maintenance Fee - Application - New Act 2 2006-01-03 $100.00 2005-11-25
Maintenance Fee - Application - New Act 3 2007-01-02 $100.00 2006-12-04
Maintenance Fee - Application - New Act 4 2007-12-31 $100.00 2007-11-27
Maintenance Fee - Application - New Act 5 2008-12-31 $200.00 2008-12-01
Request for Examination $800.00 2008-12-22
Maintenance Fee - Application - New Act 6 2009-12-31 $200.00 2009-12-02
Maintenance Fee - Application - New Act 7 2010-12-31 $200.00 2010-11-17
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
MARINE POLYMER TECHNOLOGIES, INC.
Past Owners on Record
FINKIELSZTEIN, SERGIO
VOURNAKIS, JOHN N.
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Abstract 2005-06-27 2 67
Claims 2005-06-27 7 225
Drawings 2005-06-27 1 15
Description 2005-06-27 56 3,435
Representative Drawing 2005-06-27 1 14
Cover Page 2005-09-19 1 43
Description 2010-09-15 56 3,474
Claims 2010-09-15 8 285
Drawings 2010-09-15 1 24
PCT 2005-06-27 3 80
Assignment 2005-06-27 7 277
Prosecution-Amendment 2010-03-15 2 66
Prosecution-Amendment 2008-12-22 1 41
PCT 2005-06-28 3 150
Prosecution-Amendment 2010-09-15 19 816
Prosecution-Amendment 2011-04-11 4 170